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Abbreviations 
aa  amino acid 
AB  antibiotics 
Ag  antigen 
Amp  ampicillin resistance cassette 
APC(s)  professional antigen presenting cell(s) 
BCCP  biotin carboxyl carrier protein 
BG(s)  bacterial ghost(s) 
bp  base pair 
cfu   colony forming units 
CM   cytoplasmic membrane 
CPS   cytoplasmic space 
CTLs  cytotoxic T-cells 
dH2O   deionized water 
E. coli   Escherichia coli 
Her-2/neu Human epidermal growth factor receptor 2 
HLA  human leukocyte antigen 
hm  herceptin mimotope 
Ig  immunoglobulin  
IL   interleukin 
IMP   inner membrane protein 
IM   inner membrane 
kb   kilo base pairs 
kDa   kilo Dalton 
l   liter 
LacIq  repressor of lac operon 
LacZα  gene encoding the lacZα protein 
LB   lysogeny broth 
LE  Lysis Efficiency 
LI  lysis induction 
LPS   lipopolysaccharide 
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M  molar 
mM  milli molar 
M13  intergenic region, origin of replication (+ -) 
malE  gene encoding the maltose binding protein 
MCS   multiple cloning site 
MBP   maltose binding protein 
MBP-467 maltose binding protein – peptide 4, 6, 7 fusion protein 
MBP-467ivb maltose binding protein – peptide 4, 6, 7 fusion protein with an in vivo 
biotinylation sequence 
MBP-hm maltose binding protein - herceptin mimotope fusion protein 
MBP-hmivb maltose binding protein - herceptin mimotope fusion protein with an in 
vivo biotinylation sequence 
mg  milligram 
µg  microgram 
MHC   major histocompatibility complex 
min  minutes 
μl  micro liter 
nm   nanometer 
ng   nanogram 
OD600    optical density at λ= 600 nm 
OM   outer membrane 
OMP   outer membrane protein 
ORF   open reading frame 
PAGE  polyacrylamid gel electrophoresis 
PBS   phosphate-buffered saline 
PCR  polymerase chain reaction 
pMB1  origin of replication  
PPS   periplasmic space 
pSIP  self immobilizing plasmid 
PTAC  promotor of malE 
rop  regulation of plasmid DNA replication by antisense RNA 
sdH2O  sterile deionized water 
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TA   target antigen 
TT  tetanus toxin 
WB   western blot 
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1. Zusammenfassung 
1.1 Zielsetzung 
Her-2/neu (human epidermal growth factor receptor 2) steht als Onkogen im Mittelpunkt 
vieler Bestrebungen ein therapeutisches Mittel gegen Brustkrebs zu entwickeln. Als 
Mitglied der Familie der epidermalen Wachstumsfaktorrezeptoren (EGFR) ist es in 30% 
der Brust-und Prostatakarzinomen überexprimiert und ist mit einem progressiven Verlauf 
der Krankheit und einer hohen Rückfallquote verbunden [1-3] 
An der Medizinischen Universität Wien wurden Peptide, die Teilstrukturen des 
Oberflächenrezeptors darstellen, sogenannte Mimotope, auf deren Immunogenität 
untersucht. Einige molekulare Mimikripeptide führten in Mäuseversuchen zu Induktion 
von anti Her-2/neu Antikörper, die eine Inhibition des Tumorwachstums zur Folge hatte 
[4]. Ziel laufender Studien ist, die Qualität der Immunantwort zu verbessern und mit 
geeigneten Adjuvanzien  sowohl eine B- also auch T-Zell Antwort auszulösen. 
Dafür sollen in dieser Arbeit die erfolgreichsten Peptide dieser Studien für das Delivery 
mittels der Bacterial Ghost Platform Technology ausgewählt werden. Die 
Peptidsequenzen P4, P6 und P7, lineare Epitope von Her-2/neu, sollen gekoppelt, als 
Multiepitop in den Plasmidvektor pMal-p2x kloniert und in Escherichia coli (E. coli) 
transformiert werden. Der resultierende Vektor pMal-467 erzeugt durch IPTG-Induktion 
eine Maltose-Bindeprotein (MBP) Fusion mit den Peptiden p467. Die Signalsequenz von 
MBP leitet das MBP-467 Fusionsprotein in das Periplasma des Bakteriums. Ebenso soll ein 
Konformationsepitop von Her-2/neu, Herzeptin Mimotop (hm), in den Vektor kloniert 
und als MBP-hm exprimiert werden. Das Periplasma sollte vor allem diesem über 
Schwefelbrücken zirkularisierten Mimotop durch die oxydative Umgebung gute 
Voraussetzungen bieten, um die vorgesehene Konformation, die ja nur als solche 
immunogen ist, einzunehmen. Zur Produktion von Bacterial Ghosts (BGs) soll die 
Expression dieser Fusionsproteine mit nachgeschalteter Protein E vermittelter Lyse 
durchgeführt werden. Resultat ist eine nicht lebensfähige Bakterienhülle, deren 
periplasmatischer Raum mit dem Fusionsprotein gefüllt ist. Diese mit Tumorantigenen 
bestückten BGs sind als Vakzin konzipiert, das durch aktive Immunisierung eine 
präventive Langzeitimmunität gegen Brutkrebs erzeugen soll. 
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1.2 Ergebnisse  
In Vorversuchen mit MBP-467 Fusionsproteinen produzierenden E.  coli wurde die MBP-
467 Expression zuerst indirekt mit αMBP, und anschließend direkt mit p467 spezifischen 
Antiseren mittels Western Blot Analyse nachgewiesen. Nach der Kotransformation von E. 
coli mit dem Lyseplasmid pGLysivb und dem Expressionsplasmid pMal-467 wurden 
Vorversuche zur Expression mit nachfolgender Protein E vermittelten Lyse erfolgreich 
abgeschlossen. Eine Lyseeffizienz von 99,9% wurde erreicht und E. coli NM522 (pGLysivb, 
pMal-467) ging daraufhin in die Produktion. In einem 20l Fermenter wurden BGs 
produziert, sie wurden dann geerntet, gereinigt und lyophilisiert. Das fertige Produkt 
wurde an der Medizinischen Universität von Wien  in einer Immunisierungstudie an Balb-
c Mäusen getestet, und es konnte eine Induktion peptidspezifische Antikörper 
nachgewiesen werden.  
Vorversuche für das zyklische Herzeptin Mimotop verliefen im Rahmen dieser Arbeit nicht 
erfolgreich. Die Expression wurde in verschiedenen Bakterienstämmen ausgetestet, 
unterschiedliche Methoden des Zellaufbruchs wurden untersucht, ebenso chemische 
Renaturierung zur Konformationserkennung und die Expressionsdauer und 
Zusammensetzung des Lysepuffers wurden variiert. DNA Sequenzierung des klonierten 
Vektors pMal-hm zeigte zwar, dass das Mimotop im korrekten Leserahmen war und somit 
als Fusionsprotein erzeugt werden sollte, aber ein eindeutiger Nachweis über den Her-
2/neu spezifischen Antikörper Trastuzumab (Handelsname Herzeptin) gelang nicht. Der 
Nachweis über den MBP-Teil zeigte in der Western Blot Analyse vermutlich überwiegend 
ein Abbauprodukt des Fusionsproteins, nur bei einzelnen Klonen war eine schwache 
Bande für die zu erwartende Peptidgröße  sichtbar. Das Ausmaß der Expression, des 
Transports und der korrekten Faltung des Proteins war also entweder für einen Nachweis 
zu gering, oder das Fusionsprotein war instabil und wurde abgebaut.  
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2. Summary 
2.1 Objectives 
In the development of therapeutic agents for treatment of breast cancer, many studies 
focus on Her-2/neu (human epidermal growth factor receptor 2). This oncogen that is a 
member of the human epidermal growth factor- receptor- family is over expressed in 
∼30% of breast and prostate carcinoma and linked to poor prognosis and a high cancer 
relapse [1-3]. 
Studies conducted at the Medical University of Vienna evaluate the anti-tumor potential 
of several mimotopes, which are peptide structures displaying parts of the extracellular 
domain of Her-2/neu in this case. Immunization of mice with the peptide mimics elicits 
Her-2/neu-specific antibodies inhibiting tumor progression [4]. Ongoing studies aim to 
further increase the efficacy of immune response by the use of adjuvants, which are 
capable of eliciting both B cell and T cell immunity. 
To do this, the most promising peptides out of their studies should be used for delivery 
with the Bacterial Ghost Platform Technology. Peptides 4, 6 and 7 - linear epitopes of Her-
2/neu - should be coupled as multiepitope, cloned into the vector pMal-p2x and 
transformed into E. coli.  By induction of IPTG a fusion protein of the maltose binding 
protein (MBP) and p467 is produced (MBP-467). The signal sequence of MBP directs the 
fusion protein to the periplasmic space (PPS). In addition a conformational epitope of 
Her-2/neu, herceptin mimotope (hm), should be cloned into the vector. The oxidative 
surrounding of the periplasmic space should enable disulfide bridging especially for the 
circularized mimotope - which is very important since the natural conformation is 
essential for immunogenicity. Production of BGs should be accomplished by expression of 
these fusion proteins - followed by E-mediated lysis resulting in non-living bacterial cell 
envelopes carrying the desired fusion proteins in the PPS. Active immunization with 
tumor antigen loaded BGs should generate preventive long term immunity against breast 
cancer. 
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2.2 Results  
Preliminary growth and expression studies showed positive evidence of MBP-467. The 
fusion protein was first detected indirectly by αMBP and then via p467 specific immune 
sera in western blot analysis. Cotransformation of E. coli with the lysis plasmid pGLysivb 
and expression plasmid pMal-467 and subsequent expression and lysis tests were 
successfully completed. Lysis efficiency resulted in 99.9% and E. coli NM522 (pGLysivb, 
pMal-467) was used for BG production in a 20l Techfors fermenter. After harvesting, the 
BGs were purified - and lyophilized. The final product was tested at the Medical University 
of Vienna. Immunizations of Balb-c mice showed the induction of p467 specific 
antibodies. 
Preliminary experiments for detection of the circularized herceptin mimotope were not 
successful. Expression was tested in different bacterial strain, different methods of cell 
disruption were tried out, expression time and composition of lysis buffer were varied, 
also attempts for chemical renaturation were made. Although DNA-sequencing of the 
vector showed the mimotope in the correct reading frame, detection with the 
monoclonal antibody Trastuzumab (trademark Herceptin) was not possible. Detection of 
the MBP portion by western blot analysis showed mainly a degradation product of the 
fusion protein and only for individual clones a faint band at the anticipated molecular 
weight of the target protein. The degree of expression, transport or correct folding of the 
protein was either too low to be detected or due to instability the fusion protein was 
degraded. 
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3. Introduction 
3.1 Cancer and the need for therapeutic vaccines 
According to the latest statistics, cancer is responsible for 7.6 million deaths each year 
worldwide. The number of new cases per year is 10 million, with 60% of those cases 
occurring in developing countries, mainly liver-, stomach- and cervical cancer. Prostate-, 
colon- and breast cancer prevail in developed countries [5].  
Although substantial improvements have been made in mortality due to cancer in the last 
30 years with the use of surgery, combined with radiation, chemotherapy and endocrine 
manipulation, these improvements are limited to developed countries having a functional 
health care system [6]. Furthermore, these therapies are aiming to gain control of the 
disease, but as they are not specifically targeting tumor cells only, they are damaging as 
well normal tissues to a certain extent.  Moreover these therapies often go along with 
appearance of resistant tumor cells escaping the treatment, resulting in cancer relapse [7-
9].  The invention of molecularly targeted therapy provides the opportunity to specifically 
interact with regulatory pathways of malignant proliferation. For example antibody 
treatment with Trastuzumab (Herceptin), currently a standard monotherapy of advanced 
breast cancer overexpressing the human epidermal growth receptor 2 (Her-2/neu) 
oncoprotein [10], is inhibiting malignant cell proliferation by binding the extracellular 
domain of Her-2/neu and blocking the downstream signaling [11]. But it is very cost 
intensive, needs repeated application and is limited by inadequate tissue distribution 
[12]. In summary, the limited access to affordable health care together with the 
mechanisms of therapeutical resistance of tumors to conventional therapies requires new 
cancer therapies and ways for cancer prevention. Using cancer vaccines would be a highly 
attractive approach for cancer management. 
One of modern medicines greatest achievement so far is immunization against infectious 
diseases. Preventive vaccine administration erased small pox and polio and decreased 
mortality of several other infectious diseases.  
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Why is it so difficult to develop cancer vaccines? 
When the role of cytotoxic T-cells in destroying cancer cells was recognized the focus in 
cancer vaccine research was directed on primarily tumor antigens recognized by T-cells. 
While humoral immune response (antibody response) is essential for fighting infectious 
disease by eliciting antibodies against foreign antigens with limited immunoregulation, 
cancer is controlled by cellular immunity (T-cell response) but T-cell response is often 
involved in immunoregulatory pathways that contribute to continued tumor persistence 
and proliferation [13]. Even tumor cells develop from normal cells and have self signals, 
the immune system is able to recognize them as a threat. But with time tumor cells 
acquire characteristics which allow them to escape immune surveillance. “Immune 
escape” is one back up mechanism for tumor cells, in which they alter their surface 
structure (e.g. MHCΙ ), masking them from the immune system. Tumor cells are also 
capable of mobilizing regulatory T-cells and are thereby suppressing the immune 
response [14]. Several escape mechanisms have been described [15] indicating the 
importance of context and time of tumor antigen detection by the immune system and 
also for cancer vaccine based strategies.  
Developing anti-tumor vaccines based on active immunization was often aiming to 
generate a strong anti-tumor T-cell reactivity. Cytotoxic T-cells (CTLs) are important 
effector cells against cancer, but the high frequency of human leukocyte antigen Class Ι 
down regulation in primary breast cancer and other malignancies [16-20] and thereby 
leading to immune escape redirected the attention of several research groups to 
successes seen with anti-cancer antibodies that may be important for tumor rejection 
[21]. Considering the limitations of passive antibody application mentioned above for 
Trastuzumab, an active immunization against cancer eliciting antibodies of the desired 
type might be biologically important to develop a potent anti-tumor vaccine. 
3.2 Her-2/neu, a target for immunological attack 
Breast cancer is with 17.2% of all tumor cases the most common cancer in women in the 
eastern mediterranean region and the leading cause of cancer mortality worldwide. The 
proto-oncogene Her-2/neu is a member of the ErbB protein family, also known as the 
epidermal growth factor receptor family. Her-2/neu is modestly expressed in normal 
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adult tissues [22] and over expressed in ∼30% of primary breast- and prostate cancer [23, 
24] leading to increased responsiveness to growth factors of the EGF family and resulting 
in malignant proliferation [25]. Overexpression is related to a high cancer relapse and to a 
more aggressive course of the disease in general, resulting in poor survival rates. These 
findings made Her-2/neu a target for developing anti cancer therapeutic agents.  
As the anti Her-2/neu antibody 4D5 showed inhibitory effects in mice [26], a humanized 
form , termed Trastuzumab, was tested in clinical trials showing an increased survival rate 
of patients with Her-2/neu over expressing breast tumors [11]. Besides Trastuzumab a 
large number of antibodies against Her-2/neu were developed which show different 
properties. Depending on the receptor binding site of the antibodies, they showed 
inhibitory or enhancing properties [27].  Therefore immunization with whole antigen can 
lead to opposing biological effects, whereas epitope specific vaccination may induce only 
wanted humoral immune responses, effective to treat cancer.  
3.3 Selection of predicted B cell epitopes 
Two different strategies to obtain peptide antigens of Her-2/neu for immunization 
experiments were conducted at the Medical University of Vienna, Department of 
Pathophysiology, Prof. Wiedermann. One gaining linear epitopes consisting of three 
peptides (p4, p6, p7) and the other obtaining a circularized epitope (QMW, Herceptin 
mimotope), which were later on used as peptide antigens in Bacterial Ghost (BG) delivery 
in this work. 
Computer aided analysis 
This analysis used algorithms locating surface exposed regions that are most likely 
involved in antibody binding. The epitopes were scanned for hydrophilicity, accessibility, 
flexibility, charge distribution or secondary structure propensities [28]. Seven putative B 
cell epitopes of the human extracellular domain of Her-2/neu were selected and tested in 
proliferation assays and in complement dependent- and antibody dependent- cell lysis 
(ADCC) experiments [4]. The tested epitopes were not equally immunogenic; p4 as well as 
a combination of p6 mixed with p7 were able to induce peptide specific antibody levels, 
primarily of the IgG1 isotype. In cell proliferation assays epitopes p4, p6 and p7 led to a 9–
14 
 
16% inhibition of the tumor cell proliferation in vitro and in ADCC experiments to a 31–
46% lysis of Her-2/neu over expressing tumor cells. 
Phage display technique 
For eliciting a specific humoral and cellular immune response peptides from 6 to 20 
amino acid length can be used.  Peptides that mimic the structure of an epitope are 
referred to as mimotopes. Using the phage display technique mimotopes of the 
extracellular domain of Her-2/neu were selected. A phage library can contain up to 10
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different peptides bound to the phages minor coat protein pΙΙΙ or the major coat protein 
pVΙΙΙ. Biopanning the libraries with the inhibitory monoclonal antibody Trastuzumab 
selects the mimicking peptides and they can further be enriched [29, 30]. Three rounds of 
biopanning were performed, using a phage library expressing cystein-flanked 
dekapeptides circularized by disulfide bridging. Five insert sequences were deduced from 
94 positive phage clones selected by the criteria of the highest frequency of detection 
found in colony screenings, the highest intensity of recognition by Trastuzumab and 
satisfying mimicry test results [31]. The most promising candidate was the herceptin 
mimotope C-QMWAPQWGPD-C proved to elicit antibodies recognizing the original 
antigen Her-2/neu. 
3.4 Bacterial Ghost System 
Bacterial Ghosts (BGs) are the product of a genetically controlled process called E-lysis. 
During the infectious cycle of bacteriophage ΦX174 gene E is expressed to release phage 
particles from the infected E. coli [32]. By cloning and expression of gene E in E. coli was 
proved that the gene product, protein E, is sufficient to cause lysis [33]. Protein E is highly 
hydrophobic, 91aa long, with a mass of 10.5kDa [34]. It tends to assemble at  potential 
division zones and at the polar sites, oligomerizes into a transmembrane tunnel structure 
[35], and thereby fuses the inner and outer membrane of the  Gram
−
 bacteria. The 
formation of the lysis tunnel (40-200nm) was described to go through three phases [36]. 
In phase one protein E integrates into the inner membrane, with the C-terminal part 
directing to the cytoplasm. Phase two is marked by a conformational change, the C-
terminal part migrates across the inner membrane, most probably due to a cis-trans 
isomerization of protein E in an α-helical region of domain 1 [37]. In phase three the inner 
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and outer membrane fuse, whereby the C-terminal part is reaching the surface of the 
outer membrane. Thus BGs are formed sealing the periplasmic space and releasing all the 
cytoplasmic content into the medium due to the change of osmotic pressure between cell 
interior and the surrounding media. Pictures of the efflux of bacterial cytoplasm and the 
fusion of inner and outer membrane are shown in Fig 3-1 and Fig 3-2.  
 
Fig 3-1  High resolution field emission scanning electron micrograph of the expulsion of the cytoplasmic 
content during BG formation[38] 
 
Fig 3-2 Transmission electron micrograph of lysis tunnel formation [39] 
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3.4.1 Lysis induction on a molecular basis 
The earliest lysis studies were performed with the toxic gene E under the control of a lacΙ 
repressor/promotor system (lac PO-lacI
q
). Further development proved the temperature-
sensitive λ-system (λpL/λpR-cI857) to be more quick and efficient with no need for adding 
chemical substances for lysis induction (LI) by temperature upshift above +30°. The next 
step forward was to reach more favorable growth rates at temperatures at about +35°C 
before E-mediated LI. Therefore mutations of the λpL/λpR-cI857 repressor/promotor 
system were analyzed for altered temperature conditions. A mutation in the OR2 operator 
region of the λpR was detected resulting in tight repression of gene E up to +38°C [40, 
41]. LI is currently done by a temperature upshift of the culture to +40 and +42°C, 
respectively. This lysis plasmid is also available with an in vivo biotinylation sequence (ivb) 
at the C-terminus of gene E and can therefore serve as a tool for detection of protein E. 
The molecular weight of protein Eivb is 12.7kDa. A scheme of this lysis plasmid pGLysivb 
(6.1.3) used in this work is shown in Fig 3-3.  
 
Fig 3-3 Scheme of lysis plasmid pGLysivb.  
 
MOB*: mutated mobilization sequence (mobilization frequency: 3x10
-2
) Gent: gentamycin resistance 
cassette cI875: thermo sensitive phage λ repressor cΙ PRM: „maintenance“promoter of the phage λ  PRmut: 
mutated promotor of the phage λ PR  Eivb: gene E with ivb sequence fusion rep: broad-host-range origin of 
replication 
3.4.2 BGs for vaccine application 
During production of BGs all their natural surface structures are preserved. Major 
immune stimulating elements like lipopolysaccharides, monophosphoryl lipid A, 
peptidoglycan or flagella, known as pathogen-associated molecular patterns are 
recognized by antigen presenting cells triggering the innate immune system. Recognition 
and phagocytosis by antigen presenting cells through various surface receptors like 
complement receptors and toll like receptors has been shown [42]. Their intrinsic 
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adjuvant properties enables BGs also to induce humoral and cellular immune responses, 
shown in animal experiments [43].  
This opens up a broad range of applications. A wide range of Gram
−
 bacteria can be used 
for BG production and can be applicated as vaccines directly [44]. Using recombinant DNA 
technology BGs can be used as carrier of foreign antigens in various ways. Antigens can be 
attached to the inner or outer membrane via membrane anchors, transported to the 
periplasm as maltose binding protein fusions (MBP-fusion) or coupled to other PPS 
transport signal sequences. Antigens can also be fused to S-layer sequences [45] forming 
sheet-like self assembling superstructures in the cytoplasm, resisting the expulsion during 
E-lysis. When coupled to a PPS signal sequence or to MBP, recombinant S-layers can also 
be transported to the periplasm. BGs can be loaded with active substances [46], either as 
liquid or absorbed to the lipid compartment, or specifically attached by using for example 
membrane anchored streptavidin binding a biotinylated substance or Ag to the inside of 
the cytoplasmic membrane. And they can also be loaded with DNA either by unspecific 
binding by simple resuspension of BGs in DNA solution or via specific membrane 
attachment using self immobilizing plasmids (pSIP) anchored by DNA-binding molecules 
(lacΙ) [47]. A schematic overview is given in Fig 3-4. 
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Fig 3-4 Different methods for AG presentation in the BG envelope complex—BG themselves carry native Ag 
(AG: LPS, OMP, IMP, TCP, flagella, pili)— target Ag (TA) may be presented on the cell surface via fusion with 
OmpA(1)—the PPS can be loaded with TA via MBP-SbsA-fusion proteins (1), by fusion of the TA with MBP 
(2) or as sole TA using the gene III signal sequence (3) Protein TA may be incorporated into the IM via E’, L’ 
or E’/L’-anchoring (1-3), biotinylated AG can be attached to E’-FXa-StrpA membrane anchors (1), DNA 
carrying the lac operator site can be attached to L’-anchored lacI repressor molecules (3);  whole figure 
from [48] 
Subunit vaccines are normally poor immunogenic and need adjuvants to potentiate the 
immune response to target antigens. The diverse capacity of BGs carrying foreign 
antigens combined with their intrinsic adjuvant properties can be used to design new 
vaccine candidates without the need of additional adjuvants. 
3.5  pMal-p2x Protein Fusions 
The pMal-p2x vector provides the prerequisite for expression of proteins from cloned 
genes in the PPS. Insertion of the gene downstream from the malE gene, encoding the 
maltose binding protein (MBP), results in the expression of a MBP fusion protein [49, 50]. 
19 
 
The vector expresses the malE gene with its signal sequence fused to the lacZα gene. A 
polylinker site between malE and lacZα provides restriction sites for inserting the gene of 
interest. By using an α-complementing host insertion results in a blue to white color 
change of the colonies when using Xgal plates. The system uses the strong “PTAC” 
promoter and the malE translation initiation signals to give high-level expression of the 
cloned sequences after induction with IPTG [51, 52]. The vector is also carrying the lacIq 
gene coding for overexpression of the Lac repressor, keeping the expression in absence of 
IPTG low. 
pMal vectors are available in different versions [53]. For this work pMal-p2x was used 
which includes the signal sequence for transport to the periplasmic space. Successful 
export to the periplasm allows folding and disulfide bond formation of the protein. A 
schematic drawing of pMal-p2x is shown in Fig 3-5, a more detailed illustration of the 
MCS with marked restriction sites used in this work is given in Fig 3-6. 
 
Fig 3-5 pMal-p2x vector. Arrows indicate the direction of transcription. Unique restriction sites in the 
polylinker are listed in the line at the bottom [53]. 
malE: gene coding for MBP lacZα: gene encoding the lacZα protein rrnB terminator: a portion from the rrnB 
operon, containing two terminators derived from the vector pKK233-2, prevents transcription originating 
from PTAC from interfering with plasmid functions Amp
r
: ampicillin resistance cassette M13 ori: intergenic 
region, origin of replication (+ -) pBR322 ori: origin of replication (pMB1) lacIq: repressor of lac operator PTAC 
:  promotor of malE 
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Fig 3-6 Multiple cloning site of the vector pMal-p2x. Restriction enzymes indicated by red frames were used 
in this work for insertion of DNA coding for epitopes of the tumor oncogen Her-2/neu.  SacΙ and SalΙ were 
used to insert p467; BamHΙ and SalΙ to insert hm. 
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4. Results 
4.1 Theoretical design of new expression plasmids carrying peptide epitopes of the 
oncogenic protein Her-2/neu: pMal-467and pMal-467ivb 
DNA fragments coding for extracellular domains of the human tumor antigen Her-2/neu 
were cloned into the ORF of malE of two vectors, pMal-p2x and pMal-ivb [54], targeting 
expression of MBP fusion proteins. Preliminary studies at the Medical University of 
Vienna suggested three peptide epitopes which induced humoral immune response with 
anti tumor activity in their study [55]. Sequences of these peptides 4, 6 and 7 (p467) were 
coupled and linker sequences GGGGGC and GGG were inserted for effective epitope 
exposure (Fig 4-1). 
 
Fig 4-1 Peptide sequences of p4, p6 and p7. Peptide sequences are shown in black, green letters show the 
linker sequences and red letters the sequences of the restriction sites SacΙ, BamHΙ, XbaΙ and SalΙ, which 
were inserted for this work. 
The sequence was codon optimized for E. coli, using the software GeneRunner. Additional 
restriction sites (SacΙ, BamHΙ, XbaΙ and SalΙ) were inserted together with a cystein after 
SacΙ to bring the Her-2/neu fragment into the malE reading frame to allow transport of 
the fusion protein into the PPS. The range of Her-2/neu peptide sequences plus the DNA 
sequences (194bp) used in the following work is shown in Fig 4-2. Backbone vectors pMal-
p2x and pMal-ivb and resulting final expression vectors pMal-467-lacZα and pMal-467ivb-
lacZα are shown in Fig 4-3 and Fig 4-4. They lack a stop codon before lacZα and therefore 
the recombinant proteins contain the lacZα at the C-terminus. To simplify matters the 
pMal- fusions will hence be indicated without lacZα in the text. 
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Fig 4-2 p467: Amino acid and DNA sequence of peptides 4, 6 and 7. The sequence was translated into E. coli 
codon usage, linked with appropriate restriction sites and a cystein after the SacΙ restriction site was 
inserted for cloning it into the correct ORF of malE. The length of the multiepitope insert p467 is 194bp. 
 
Fig 4-3 Cloning of pMal-467. Insertion of the DNA sequence of 467 into the MCS of the backbone vector 
pMal-p2x was done using the restriction enzymes SacΙ and SalΙ. Gene malE is under the control of the IPTG 
inducible PTAC promotor. Addition of 2mM IPTG leads to expression of the gene product MBP-467-lacZα  
LacIq: repressor PTAC: promotor of malE: gene encoding the N-terminal part of Maltose Binding Protein 
LacZα: gene encoding the lacZα protein Amp: ampicillin resistance cassette M13: intergenic region, origin of 
replication (+ -) pMB1: origin of replication  rop: regulation of plasmid DNA replication by antisense RNA. 
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Fig 4-4 Cloning of pMal-467ivb. Insertion of the DNA sequence 467 into the MCS of the backbone vector 
pMal-ivb was done using the restriction enzymes SacΙ and SalΙ. Gene malE is under the control of the IPTG 
inducible PTAC promotor. Addition of 2mM IPTG leads to expression of the gene product MBP-467ivb-lacZα. 
LacIq: repressor PTAC: promotor of malE: gene encoding the N-terminal part of Maltose Binding Protein 
LacZα: gene encoding the lacZα protein Amp: ampicillin resistance cassette M13: intergenic region, origin of 
replication (+ -) pMB1: origin of replication  rop: regulation of plasmid DNA replication by antisense RNA. 
Fusion proteins MBP-467 and MBP-467ivb expression is driven by the IPTG inducible PTAC 
promotor that is repressed in the absence of IPTG by the lacI repressor. Fusion proteins 
will be transported to the PPS by the signal sequence (SS) of MBP. Unified atomic mass 
units in Dalton of MBP, MBP-467 and MBP-467ivb and length in bp are listed in Tab 4-1. 
Sequence of vector pMal-p2x is provided by NEB [56] but no sequence specification of the 
SS for the PPS transport. According to the manual of the pMAL™ Protein Fusion and 
Purification System the pMal-p2x includes the “normal” SS of the periplasmic MBP of E. 
coli. Transport to the PPS leads to a truncated mature peptide devoid of the SS. Database 
of UniProtKB/Swiss-Prot provides the whole peptide sequence including the SS [57], 
which was used for calculations of the mature periplasmic protein mass in this work. 
Complete sequences are stored at the plasmid data base at BIRD-C. An overview of all 
plasmids constructed in this work is given in 7. 
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Peptide Mass incl. SS 
[kDa] 
Mass – SS 
[kDa] 
Length incl. SS 
[bp] 
Length –SS 
[bp] 
Recombinant MBP- lacZα 53.4 50.6 1464 1386 
E. coli MBP 43.4 40.7 1188 1110 
MBP-467-lacZα 57.0 54.2 1572 1494 
MBP-467ivb-lacZα 58.8 56.0 1620 1542 
MBP*  42.5
) 
  
Tab 4-1 Atomic mass units of E. coli MBP and MBP fusion proteins in kDa. Mature peptides in the PPS lack 
SS. Recombinant MBP: maltose binding protein from the expression vector pMal-p2x, E. coli MBP: 
chromosomal encoded maltose binding protein of E. coli, MBP-467: MBP-467 fusion protein, MBP-467ivb: 
p467 fusion protein coupled to ivb, still fused to lacZα, MBP*: breakdown product of fusion protein  
)protein size is given in literature [53] 
4.1.1 Cloning of pMal-467and pMal-467ivb 
Two possibilities for acquiring the 194bp DNA of p467 were taken into consideration for 
cloning. One was the ordering of a synthetic ds DNA from GenArt (Regensburg, Germany). 
The other possibility was ordering ss DNA molecules which were completed using PCR. 
The latter possibility was followed first and as it was told by the customer service of VBC 
Genomics (Vienna, Austria) that synthesis of correct sequences up to 120bp can be 
guaranteed. The p467 sequence was ordered in two parts, the N-terminal part sense 
p467 and the C-terminal part antisense p467. A long primer for each construct was used 
to fill up in a first PCR reaction and two short primers were used for each construct to 
amplify in the second PCR reaction. Sequences of sense, antisense and primers are given 
in Fig 4-5 and a scheme of the PCR reactions in Fig 4-6. Restriction digest of amplified 
fragments p46 and p7 with XbaΙ was followed by ligation. The whole multiepitope p467 
was then inserted in the MCS of pMal-p2x using the flanking restriction sites SacΙ and SalΙ 
and transformed into E. coli NM522. Several attempts produced constructs which showed 
base deletions and mismatch regions by sequencing of malE-p467 region from “positive” 
clones. To overcome this problem it was decided to go for the second strategy and to 
order the p467 fragment synthesized by GenArt. 
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Fig 4-5 Sequence of the multiepitope p467 and sequences used for construction of the multiepitope. a) 
shows the whole multiepitope with restriction sites which was aimed to construct with the sense, antisense 
and corresponding primers shown in b) 
 
Fig 4-6 Construction of the multiepitope p467 by PCR. a) In the first PCR reaction the sense467 and 
overlapping P6antisense was filled up indicated by the pink dotted line generating the p46 fragment. The 
second PCR was performed with  5’467primer and p46primer and amplified the p46 fragment. b) in the first 
PCR antisense 467 and the long overlapping P7primer was filled up indicated by the pink dotted line 
generating the P7 fragment. The second PCR reaction amplified the P7 fragment.  Restriction of amplified 
fragments from a) and b) with XbaΙ and following ligation was expected to give the whole multiepitope 
p467 shown in c) 
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The synthetic 194bp DNA was assembled upon demand (Fig 4-2) from synthetic 
oligonucleotides by GenArt. The fragment was cloned by GenArt into pPCR-Script using 
SacI and KpnI restriction sites flanking the p467 sequence. The plasmid 053935pPCR-
Script was purified from transformed bacteria and the final construct verified by 
sequencing. 10µg of the plasmid were lyophilized and delivered by GeneArt. Fig 4-7 
shows the plasmid map of the delivered synthetic DNA. 
 
Fig 4-7 Synthetic gene p467 cloned into pPCR-Script using KpnI and SacI 
10µg of the lyophilized pPCR-Script vector were resuspended in 50µl sterile H2O, left for 
one hour at room temperature and stored at -20°C for further use. 5µl of the solution 
were used for MOPS transformation into E. coli NM522. Positive clones were selected on 
LB agar plates with ampicillin. The p467 fragment was obtained by double digest of the 
pPCR-Script vector using the enzymes SacΙ and SalΙ, which were included in the sequence 
for cloning reason. The vectors pMal-p2x and pMal-ivb were also prepared for cloning by 
cutting with SacΙ and SalΙ. The unique restriction sites in the MCS of both vectors ensure 
orientated cloning of p467 into the ORF of malE. Separation of fragment and vectors was 
done by gel electrophoresis (Fig 4-8 and Fig 4-9) and purification by subsequent 
extraction using PCR Purification Kit from Quiagen (Duesseldorf, Germany). 
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Fig 4-8 Restriction analysis of pPCR-Script vector on 2% agarose gel. The product of the double digest of 
pPCR-Script vector was loaded on lane 1-4. For DNA sizing a 50bp DNA ladder was loaded. The 194bp 
fragment p467 is visible at the right size of ∼ 200bp. M: 50bp ladder 
 
Fig 4-9 Restriction analysis of pMal-p2x and pMal-ivb vectors on 1% agarose gel. The product of the double 
digest with SacΙ and SalΙ of vectors pMal-p2x (lane1 – 3) and pMal-ivb (lane 4 – 6) are visible as linearized 
vectors at the correct size. Vectors pMalp2x (6646bp) and pMal-ivb (6694bp) show the expected size and 
are reduced in size by a 78bp fragment lying between SacΙ and SalΙ . M: 1kb ladder  
Ligation of vectors pMal-p2x and pMal-ivb with the fragment p467 was done with the 
molar ratio of vector: insert = 1: 10. Both ligation products, vector pMal-467 and pMal-
467ivb, were then transformed into E. coli NM522, purified by minipreps and afterwards 
tested for the correct size by restriction digest. Cutting with the restriction enzyme 
Eco01009Ι indicates a positive clone by giving a special restriction fragment pattern for 
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the vectors. Vector pMal-467 cut with Eco01009Ι should result in 3 fragments, 
3964/2821/42, whereas the backbone vector pMal-p2x without p467 would result in two 
fragments, 6679/42. Vector pMal-467ivb cut with Eco01009Ι should result in 3 fragments, 
4012/2821/21, whereas the backbone vector pMal-ivb without p467 would result in two 
fragments, 6727/42. Another gel electrophoresis confirmed positive sized clones for these 
ligations (Fig 4-10 and Fig 4-11); digest of backbone vectors is not shown. As the p467 
fragment was supplied with a sequence protocol positive clones were not sequenced 
once again. 
 
Fig 4-10 Restriction analysis of pMal-467 on 1% agarose gel. 10 clones were cut with Eco01009I to confirm 
correct size of plasmids. Lane 1 – 20 show clone 1 – 10 consecutively loaded: odd numbers are uncut and 
following even numbers are the cut version of the same clone. (M 1kb ladder) 
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Fig 4-11 Restriction analysis of pMal-467ivb 1% agarose gel. 10 clones were cut with Eco01009I to confirm 
correct size of plasmids. Lane 1 – 20 show clone 1 - 10 consecutively loaded: odd numbers are uncut and 
following even numbers are the cut version of the same clone. (M 1kb ladder) 
Plasmids isolated from E. coli NM522 (pMal-467) c1 and E. coli NM522 (pMal-467ivb) c5 
were isolated, freshly transformed into E. coli NM522 and five clones of each stored as 
glycerin stocks at -80°C. Growth and expression was analyzed in noseflask experiments. 
4.1.2 Growth and expression of E. coli NM522 (pMal-467) and E. coli NM522 (pMal-
467ivb) 
The experiment was carried out in noseflasks containing 30ml LB and ampicillin 
(100µg/ml). Three clones of each construct were tested. To evaluate possible effects of 
recombinant protein expression on the cell viability and to verify expression of the 
recombinant protein, periodic sample were taken for western blot analysis, cfu 
determination and OD measurements according to 6.3.3.  
Expression of the recombinant protein MBP-467/MBP-467ivb of the vector pMal-
467/pMal-467ivb was induced by addition of 0.2mM IPTG when the cultures reached an 
OD600 of about 0.2. Growth diagram in Fig 4-12 shows that expression of the fusion 
protein had no negative effect on cell growth in OD as well as in cfu. Western blot 
samples were separated by a 15% SDS – PAGE. WBs analyses in Fig 4-13 and Fig 4-14 
proof expression of the MBP-467 and MBP-467ivb fusion proteins.  The ivb-sequence is 
biotinylated in E. coli in vivo and this biotin can be detected in WB using streptavidin. 
Natural occurrence of the carboxyl carrier protein (BCCP) in E. coli is used for internal 
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control for ivb detection. BCCP is encoded by the accB gene and is a component of acetyl 
CoA carboxylase. Samples exhibit protein bands at ∼58kDa, which reacted in western blot 
analysis with αMBP and α rabbit IgG-HRP, respectively streptavidin-HRP.  The WB also 
shows that the PTAC promotor is not tightly repressed before IPTG induction to reduce 
preinduced expression of MBP-467 and MBP-467ivb. This suggested addition of glucose 
to the overnight culture for following studies. 
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Fig 4-12 Growth curve of E. coli NM522 (pMal-467) and E. coli NM522 (pMal-467ivb).  
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Fig 4-13 Western blot analysis of whole cell protein extract of E. coli NM522 (pMal-467) and E. coli NM522 
(pMal-467ivb). Cells expressing the MBP-467 fusion protein (∼58kDa), 1, 2 and 3 prior (A) and after (E) 
induction. Cells expressing the MBP-467ivb fusion protein (∼59kDa), 4, 5 and 6 prior (A) and after (E) 
induction. Positive control (+) expressing the MBP (∼54kDa) of the backbone plasmid pMalp2x. The 
presence of the MBP portion of the fusion protein and the naturally occurring MBP (∼43kDa) was examined 
with αMBP and α rabbit IgG-HRP.  
 
Fig 4-14 Western blot analysis of whole cell protein extract of E. coli NM522 (pMal-467ivb). Cells expressing 
the MBP-467ivb fusion protein (∼59kDa), 5 and 6 prior (A) and after (E) lysis induction. The presence of the 
biotin portion of the fusion protein was examined with streptavidin-HRP. The biotin carboxyl carrier protein 
(BCCP) of E. coli can be detected at 22,5kDa.  
4.1.3 Recombinant protein expression and lysis of E. coli NM522 (pMal-467)  
Electro competent E. coli NM522 were transformed with pMal-467 and pGLysivb. Five 
positive clones plus E. coli NM522 (pMalp2x, pGLysivb) as control were tested for lysis 
efficiency and recombinant protein expression in this study. The experiment was carried 
out in noseflasks containing 30ml LB, ampicillin (100µg/ml) and gentamycin (20µg/ml). 
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Periodic samples were taken (according to 6.3.3) to calculate the lysis efficiency (LE) and 
to detect the expression of the fusion protein MBP-467on WB.  
Expression was induced by adding 2mM IPTG when OD600 was about 0.2. Lysis was 
induced by temperature up shift from +36°C to +42°C 60 min after induction of 
recombinant protein expression (time point 0 min). The growth and lysis diagram in Fig 
4-15 illustrates ongoing growth until lysis induction, followed by a cfu decay and drop of 
optical density, indicating lysis. The LE was determined as follows and calculations are 
shown in Tab 4-2. 
LE  = 1  	
	 . 100 
t0 ...time point of lysis induction 
t ...time point after lysis induction used for determination of LE; for this work t =120 min after 
induction 
 
Clone LE [%] 
E. coli  NM522 (pMal-467, pGLysivb) c1 99,84 
E. coli  NM522 (pMal-467, pGLysivb) c2 99,05 
E. coli  NM522 (pMal-467, pGLysivb) c3 99,90 
E. coli  NM522 (pMal-467, pGLysivb) c4 97,07 
E. coli  NM522 (pMal-467, pGLysivb) c5 99,66 
E. coli  NM522 (pMalp2x, pGLysivb) 99,73 
Tab 4-2 Lysis efficiencies (LE) calculated with cfu counts from samples before (0 min) and 120 min after LI 
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Fig 4-15 Growth and lysis of E. coli NM522 (pMal-467, pGLysivb) c1 – c5 and control E. coli NM522 
(pMalp2x, pGLysivb). Addition of 2mM IPTG was done at time point -60 min and temperature up shift from 
+36°C to +42°C at time point 0 min. The drop of cfu counts and optical density indicates lysis. 
A pre-cast 12% NuPAGE® Bis-Tris Gel was used for protein separation. The nitrocellulose 
membrane was stripped (6.2.5.3) allowing detection of the fusion protein with different 
anti sera on the same membrane. The fusion protein reacted in western blot analysis with 
rabbit anti p467 serum (Fig 4-16), mouse anti p467 serum (Fig 4-17) and purified rabbit 
anti p467 serum (Fig 4-18). E. coli NM522 (pMalp2x, pGLysivb) served as a control for 
growth and lysis and samples were not analyzed by WB. The strongest signal showed 
clone 2 by detection with the mouse serum, whereas the same clone showed the weakest 
signal by detection with rabbit serum. The mouse serum showed the least amount of 
unspecific bands and therefore lowest background signals. Samples taken after induction 
of expression exhibited a protein band at ∼58kDa (and its degradation product below at 
∼50kDa) for all sera which was absent in samples taken prior to induction.  
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Fig 4-16 Western blot analysis of whole cell protein extract of E. coli NM522 (pMal-467, pGLysivb). Bacteria 
expressing the MBP-467 fusion protein (∼58kDa), clone 1, 2 and 5 prior (A), 30 min after (B) and 60 min 
after (C) induction of expression. The presence of the 467 portion of the fusion protein was examined with 
rabbit anti p467 serum (1:100) and anti rabbit IgG-HRP (1:20000).  
 
Fig 4-17 Western blot analysis of whole cell protein extract of E. coli NM522 (pMal-467, pGLysivb). Bacteria 
expressing the MBP-467 fusion protein (∼58kDa) clone 1, 2 and 5 prior (A), 30 min after (B) and 60 min after 
(C) induction of expression. The presence of the 467 portion of the fusion protein was examined with 
mouse anti p467 serum (1:500) and anti mouse IgG-HRP (1:3000). 
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Fig 4-18 Western blot analysis of whole cell protein extract of E. coli NM522 (pMal-467, pGLysivb). Bacteria 
expressing the MBP-467 fusion protein (∼58kDa) clone 1, 2 and 5 prior (A), 30 min after (B) and 60 min after 
(C) induction of expression. The presence of the 467 portion of the fusion protein was examined with 
purified rabbit anti p467 serum (1:50) and anti rabbit IgG-HRP (1:20000).  
4.1.4 Production of E. coli NM522 (pMal-467, pGLysivb) BGs 
E. coli NM522 (pMal-467, pGLysivb) BGs were produced in 20.0l low density batch 
fermentation using a 30l Techfors-S fermenter (6.3.4, 6.3.5). Fermentation was 
performed in LB medium, supplemented with gentamycin (20µg/ml) and ampicillin 
(100µg/ml). Pre-cultures were grown in 4x500ml LB medium overnight, supplemented 
with gentamycin (20µg/ml), ampicillin (100µg/ml) and glucose (1% w/v for repression of 
recombinant protein expression). Inoculation of the fermenter was done with 870ml 
overnight culture reaching an optical density of ~ 0.1. Bacteria were grown at +35°C, at 
constant air flow of 5l/min and increased stirring rates, 100 to 300 rpm. Recombinant 
protein expression was induced by addition of 2mM IPTG 60 min prior LI. Lysis was 
induced by temperature up shift to +42°C. Final killing was done 120 min after LI by 
adding streptomycin and tetracycline (200ug/ml and 20ug/ml end concentration, 
respectively, and incubated for another 120 min. Online process data are monitored by 
the IRIS software and displayed in Fig 4-19.  
Generally the increase of oxygen in of the media during cultivation goes along with cell 
death and is expected after LI, as bacteria are no longer consuming oxygen. Although 
earlier studies proved no negative effect for this fusion protein expression on cell viability, 
oxygen increased when protein expression was induced at point -60min. The loss of 
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viability prior and after LI was calculated and is shown in Fig 4-20 and Tab 4-3. Reduction 
of viability during 60 min of recombinant protein expression was 42.08%. This value 
needs to be viewed critically since it is received from agar plates that were incubated over 
night and could therefore be attributed to a long term effect on bacteria. Thirty min of LI 
resulted in a significant decrease of living cell counts gaining a total killing of 98.69%. 
After 60 min lysis the concentration of cfu dropped below the counting range which gives 
reliable data to make extrapolations for the used sample dilutions. According to the 
manufacturer’s deposition parameters (Don Whitley Scientific), the counting range lies 
between 4.10
2
 and 4x10
5 
cfu/ml. For the 10
2
 dilution, used for plating after LI, the range 
lies between 4x10
4
 and 4x10
7
cfu/ml. From this it follows that no detectable cfu values at 
60, 90 and 120 min after lysis correspond to actual values below 4x10
4 
cfu/ml. 
Predominantly BGs were seen when investigating the sample from 120 min after LI 
through light microscopy (Fig 4-21).  
 
Fig 4-19 IRIS data curve of E. coli NM522 (pMal-467, pGLysivb) fermentation. 
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Fig 4-20 Growth and lysis curve of large scale production of E. coli NM522 (pMal-467, pGLysivb) BGs by 
fermentation.  
time point activity cfu 
-60 min +IPTG 8,39E+07 
-30 min  2,91E+07 
0 min T up shift to +42°C 1,68E+07 
30 min  2,20E+05 
60 – 120 min   ≤ 4,00E+04 * 
Tab 4-3 Cfu values during large scale BG production. Cfu dropped already before LI and continues with a 
significant drop of cfu 30 min after LI. The * marked value is a virtual value and defines the lowest cfu which 
would be detectable for a 10
2 
dilution (commonly used dilution for samples after LI) lying in the counting 
range.  
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Reduction of viability [%] prior lysis from time point -60 min to 0 min:  
1  
	
	  . 100 = 42, 08 
LE [%] within 30 min from time point 0 min to 30 min: 
1  
	
	 . 100 = 98, 69 
LE [%], including the virtual value from time point 0 min to 60 min: 
1  
	
	 . 100 = 99, 76 
 
 
Fig 4-21 Light microscopy picture of BGs 120 min after LI. 
Samples taken during fermentation were separated on a NuPAGE® 4-12%-Bis-Tris-Gel for 
MBP-467 detection, and on a NuPAGE® 12% Tris-Tricine-Gel for Eivb detection. Incubation 
of the membrane with mouse anti p467 serum and anti mouse IgG-HRP exhibits the 
expected band of MBP-467 at about 58kDa (Fig 4-22). The sample at time point -60 min 
(induction of protein expression) was taken by accident after addition of IPTG and 
therefore a band can be seen already at this time point.  At +120 min the MBP-467 band 
is missing. To find out whether transfer for this membrane portion failed or the fusion 
protein was degraded the blot was repeated with lyophilized BG samples. Fig 4-23 shows 
a strong signal at ∼58kDa which proves the presence of MBP-467. Incubation of the 
second membrane with streptavidin-HRP exhibits biotinylated E at about 13kDa. The lysis 
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protein accumulates after LI whereas the cytosolic BCCP (∼23kDa) is released through the 
lysis tunnel (Fig 4-24), mainly visible after 120 min of E-lysis. 
 
Fig 4-22 Western blot analysis of whole cell protein extracts of E. coli NM522 (pMal-467, pGLysivb) 
fermentation. Bacteria express the MBP-467 fusion protein (∼58kDa) upon induction at -60 min. Time 
points from 90 min prior (-90 min) to 120 min after LI (120 min) are shown. The presence of the 467 portion 
of the fusion protein was examined with mouse anti p467 serum (1:500) and anti mouse IgG-HRP (1:3000).  
 
Fig 4-23   Western blot analysis of whole cell protein extracts of lyophilized E. coli NM522 (pMal-467, 
pGLysivb) BGs. BGs carry the MBP-467 fusion protein (∼58kDa). Lyophilized BGs were resuspended in 
sample buffer and loaded in different concentrations: 12µg/ml (lane 1), 1, 2µg/ml (lane 2), 0, 12µg/ml (lane 
3). The presence of the 467 portion of the fusion protein was examined with mouse anti p467 serum 
(1:500) and anti mouse IgG-HRP (1:3000). 
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Fig 4-24 Western blot analysis of whole cell protein extracts of E. coli NM522 (pMal-467, pGLysivb) 
fermentation. Bacteria express the lysis protein Eivb (∼13kDa) upon induction by temperature up shift to 
+42°C at time point 0 min. The presence of the biotinylation of Eivb was examined with streptavidin-HRP. 
Eivb is accumulating and the cytosolic protein BCCP (∼23kDa) is released during lysis. 
The final killing with antibiotics was successful as no survivors were detected on the agar 
plates inoculated with undiluted samples. Harvest of the total volume of 20l followed by 
washing and lyophilization yielded in the amount of 1388mg BGs dry weight. The material 
was proved to be sterile in sterility testing. The calculated amount of particles per mg was 
1.20x 10
09
. 
4.1.5 Immunization of BALB/c mice with E. coli NM522 (pMal-467, pGLysivb) BGs 
Mice experiments were performed at the Medical University of Vienna, Department of 
Pathophysiology. Eight week old BALB/c mice (n=6/group), purchased from Charles River 
(Sulzfeld, Germany) were immunized with BGs comprising the coupled peptides 4, 6 and 7 
of Her-2/neu. BGs were injected 4 times subcutaneously in intervals of 2-3 weeks using 
different concentrations in group A (3.0mg BG-467), group B (1.0mg BG-467), group C 
(0.5mg BG-467) and control group D (3mg empty BGs) per injection. Blood samples were 
taken after the third and fourth immunization. Seven days after the second blood sample 
mice were killed and spleen was removed and cells were further analyzed in cell culture. 
4.1.5.1 Humoral immune response 
After the third immunization a blood sample was taken and analyzed. Peptide-specific 
antibodies could be detected within a 1:250 diluted serum. A significant higher titer of the 
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experimental groups versus control group shows the effective delivery of Her-2/neu 
epitopes P4, 6 and 7 by BGs (Fig 4-25, Fig 4-26, Fig 4-27). The titer was too low to compile 
a subclass profile.   
 
Fig 4-25 Peptide specific anti P4 antibodies (IgG) onto 3 subcutaneous applications of BGs. Applied 
concentration for the experimental groups was 3.0 mg (A), 1.0mg (B) and 0.5mg (C) per injection. 
Immunization of the control group (D) was done with 3mg empty BGs.  
 
Fig 4-26 Peptide specific anti P6 antibodies (IgG) onto 3 subcutaneous applications of BGs. Applied 
concentration for the experimental groups was 3.0 mg (A), 1.0mg (B) and 0.5mg (C) per injection. 
Immunization of the control group (D) was done with 3mg empty BGs.  
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Fig 4-27 Peptide specific anti P7 antibodies (IgG) onto 3 subcutaneous applications of BGs. Applied 
concentration for the experimental groups was 3.0 mg (A), 1.0mg (B) and 0.5mg (C) per injection. 
Immunization of the control group (D) was done with 3mg empty BGs. 
4.1.5.2 Cellular immune response 
Seven days after the fourth immunization spleen was removed and tested in cell culture. 
Proliferation of spleen cells was measured by H
3
 thymidin incorporation. In vitro 
stimulation with BGs-P467 did not lead to increased proliferation. IFN-gamma production 
by spleen cells was measured in the supernatants by ELISA. IFN-gamma production did 
not increase after in vitro stimulation with BGs-P467. The results correspond to earlier 
data and confirm the hypothesis, that the used Her-2/neu sequences display B-cell 
epitopes and therefore do not trigger T-cell response themselves. 
4.2 Theoretical design of new expression plasmids carrying mimotopes of the 
oncogenic protein Her-2/neu: pMal-hm and pMal-hmivb 
The DNA sequence coding for a herceptin mimotope (hm) recognized by Trastuzumab, 
was cloned into the malE ORF of vectors pMalp2x and pMal-ivb, targeting expression of 
MBP fusion proteins. Hms were generated using the phage display technique and 
selected by specifically binding to Trastuzumab at the Medical University of Vienna [31]. 
In this work the herceptin mimotope QMW (Fig 4-28a), further referred to as hm, 
circularized by disulfide bridging was supplemented with restriction sites for cloning into 
the expression plasmids. Linker sequences which should assist in circularization by 
separating the epitope from the residual fusion partner were also included. Design of hm 
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sequences for cloning into pMal-p2x (Fig 4-28b) and into pMal-ivb (Fig 4-28c and d) is 
shown below. Sequencing clones carrying the construct displayed in Fig 4-28c showed an 
unwanted stop mutation. Therefore the hm sequence displayed in Fig 4-28b was used for 
amplification via PCR (Primer sequences see Fig 4-29), allowing to exclude the stop, 
yielding to hm sequence as shown in Fig 4-28d. PCR product was used for cloning into the 
vector pMal-ivb. 
 
Fig 4-28 a) Peptide sequence of the herceptin mimotope (hm) b) hm supplemented with restriction sites 
BamHΙ and SalΙ (red letters), a linker sequence (green letters) and two stop codons, indicated by red dots, 
for cloning into vector pMalp2x c) hm supplemented with restriction sites BamHI and SalΙ (red letters), and 
linker sequences (green letters) for cloning into the vector pMal-ivb d) sequence for cloning hm into the 
vector pMal-ivb using PCR of the hm sequence displayed in b) 
 
Fig 4-29 Primer designed for amplification of hm figured in Fig 4-28b to exclude the stop codon for coupling 
MBP-hm to ivb of the vector pMal-ivb. Sequence verified vector pMal-hm was used as target.  
By designing the sequence theoretically using the software GeneRunner, the sequence 
was codon optimized for E. coli. The hm sequences were inserted into the ORF of malE to 
allow transport of the fusion protein into the PPS. The range of the hm peptide sequence 
plus the DNA sequence of the hm fusion peptide used in the following work is shown in 
Fig 4-30. Backbone vectors and final expression plasmids (pMal-hm, pMal-hmivb) are 
illustrated in Fig 4-31 and Fig 4-32. 
 
Fig 4-30 Amino acid and DNA sequence of hm. Sequence was translated into E. coli codon usage and 
inserted into the ORF of malE via MCS (BamHΙ, SalΙ) of the vector pMalp2x. Sequence for cloning into the 
vector pMal-ivb lacks the two stop codons (not shown) 
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Fig 4-31 Cloning of pMal-hm by inserting the hm DNA sequence into the MCS of the backbone vector 
pMalp2x using BamHΙ and SalΙ. Gene malE is under the control of the IPTG inducible PTAC promotor. 
Addition of 2mM IPTG leads to expression of the fusion protein MBP-hm. 
LacIq: repressor PTAC: promotor of malE malE: gene encoding the N-terminal part of Maltose Binding Protein 
LacZα: gene encoding the lacZα protein Amp: ampicillin resistance cassette M13: intergenic region, origin of 
replication (+ -) pMB1: origin of replication rop: regulation of plasmid DNA replication by antisense RNA. 
 
 
Fig 4-32 Cloning of pMal-hmivb by inserting the hm DNA sequence into the MCS of the backbone vector 
pMal-ivb using BamHΙ and SalΙ. Gene malE is under the control of the IPTG inducible PTAC promotor. 
Addition of 2mM IPTG leads to expression of the fusion protein MBP-hmivb. 
LacIq: repressor PTAC: promotor of malE malE: gene encoding the N-terminal part of Maltose Binding Protein 
LacZα: gene encoding the lacZα protein Amp: ampicillin resistance cassette M13: intergenic region, origin of 
replication (+ -) pMB1: origin of replication rop: regulation of plasmid DNA replication by antisense RNA. 
 
Fusion proteins MBP-hm and MBP-hmivb expression is driven by the IPTG inducible PTAC 
promotor that is repressed in the absence of IPTG by the lacIq repressor and the fusion 
proteins are transported to the PPS by the SS of MBP. Unified atomic mass units in Dalton 
of MBP, MBP-467 and MBP-467ivb and length in bp are listed in Tab 4-2. The DNA 
sequence of the fusion protein MBP-hmivb lacks the stop codons after the hm sequence 
and is therefore expressed with lacZα giving a MBP-hmivb-lacZα fusion, whereas the DNA 
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sequence of MBP-hm includes stop codons after the hm sequence and is expressed 
without lacZα. In the further text pMal-hmivb-lacZα is referred to as pMal-hmivb. 
Sequence of vector pMal-p2x is provided by NEB [56] but no sequence specification of the 
SS for the PPS transport . The manual of the pMAL™ Protein Fusion and Purification 
System says that the pMal-p2x includes the “normal” SS of the periplasmic MBP of E. coli. 
Transport to the PPS leads to a truncated mature peptide devoid of the SS. Database of 
UniProtKB/Swiss-Prot provides the whole peptide sequence including the SS [57], which 
was used for calculations of the mature periplasmic protein mass in this work. Complete 
sequences are stored at the plasmid data base at BIRD-C. An overview of all plasmids 
constructed in this work is given in 7. 
Peptide 
Mass incl. SS 
[kDa] 
Mass – SS 
[kDa] 
Length incl. SS 
[bp] 
Length - SS 
[bp] 
Recombinant MBP-lacZα 53.4 50.6 1464 1386 
E. coli MBP 43.4 40.7 1188 1110 
MBP-hm 47.4 44.6 1308 1230 
MBP-hmivb-lacZα 56.8 53.9 1557 1479 
MBP*  42.5
)
   
Tab 4-4 Atomic mass units of E. coli MBP and MBP fusion proteins in kDa. Mature peptides in the PPS lack 
the SS. Recombinant MBP: maltose binding protein from the expression vector pMal-p2x E. coli MBP: 
chromosomal encoded maltose binding protein of E. coli MBP-hm: MBP- herceptin mimotope fusion 
protein MBP-hmivb: herceptin mimotope fusion protein coupled to ivb, still fused to lacZα MBP*: 
breakdown product of fusion protein  
)protein size according to  literature [53] 
4.2.1 Cloning of pMal-hm and pMal-hmivb 
Hm sequences from Fig 4-28b and c were produced at VBC genomics (Vienna, Austria). 
DNA was ordered as sense and antisense DNA so that cloning into appropriate vectors 
was possible without cutting with BamHΙ and SalΙ (ordered sequence shown in black 
letters in Fig 4-33). DNA for cloning into pMal-ivb was amplified by PCR from pMal-hm 
using primers shown in Fig 4-29 to give the hm construct displayed in Fig 4-28d. 
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Fig 4-33 Sense and antisense DNA of hm. DNA in black letters was ordered so that cloning into appropriate 
vectors was possible without cutting with BamHΙ and SalΙ. Red letters display the complementary 
restriction sites present in the plasmids cut by BamHΙ and SalΙ. 
Lyophilized hm DNA was resuspended in ultrapure water (100pmol/ml) and was left on 
the shaker for 30 min at room temperature.  15µl of corresponding sense and antisense 
DNA each were unified and diluted 1:2 with ultrapure water. The mixture was then 
heated to 95°C for 10 min and let cool down to room temperature for strand annealing. 
Hm DNA was checked on an 8% PAGE (Fig 4-34), cut out from the gel and purified by DNA 
elution according to 6.2.8. Vectors pMal-p2x and pMal-ivb were prepared for cloning by 
cutting with BamHΙ and SalΙ. The unique restriction sites in the MCS of both vectors 
ensure orientated cloning of hm into the ORF of malE. Separation of the vectors was done 
by gel electrophoresis and purification by subsequent extraction using Quiagen PCR 
Purification Kit. Ligation of hm sequence and pMalp2x was done at +4°C over night, 
followed by MOPS transformation into E. coli NM522. Isolated plasmid DNA pMal-hm 
from a positive clone, checked by sequencing, was used for PCR to generate DNA 
construct hmivb. The PCR product was checked on a 2% agarose gel (Fig 4-35) the correct 
sized band was cut out from the gel and was purified using the Promega Gel Extraction 
Kit. After digest of the hmivb construct with BamHΙ and SalΙ, the DNA was purified with 
the Promega Wizard SV Gel and PCR Clean up System. The hmivb construct was ligated 
with vector pMal-ivb at 4°C over night and the ligation mix was transformed into E. coli 
NM522. Sequencing showed the correct sequence in the reading frame. 
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Fig 4-34 Strand annealing of hmivb (lane 1) and hm (lane 2) checked on an 8% PAGE.  
 
Fig 4-35 PCR product of hmivb amplification. 3µl on lane 1, 12µl on lane 2. PCR 0-control on lane 3.  
Plasmids from transformants were purified by minipreps and afterwards tested for 
correct size by restriction digest. Screening of positive clones was done with Eco0109Ι for 
pMal-hm and with KasΙ for pMal-hmivb. The fragment size after digest of pMal-hm for 
positive clones is 42/3889/2840bp, whereas the backbone vector pMal-p2x without hm 
would result in two fragments 42/6679bp.  The fragment size after digest of pMal-hmivb 
for positive clones is 1738/5076bp, whereas the backbone vector pMal-ivb without hmivb 
would be linearized giving a band at 6769bp. Plasmid preparation pMal-hm from clone 5 
on lane 4 shows the correct restriction pattern at ∼3900 and ∼2900bp and was selected 
for transformation (Fig 4-36). For pMal-hmivb the plasmid on lane 1 (cut) from clone 12 
shows the correct restriction pattern at ∼1700 and ∼5000bp and was selected for 
transformation (Fig 4-37). 
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Fig 4-36 Restriction analysis of putative pMal-hm plasmids on 1% agarose after digest with Eco0109I.  
 
Fig 4-37 Restriction analysis of putative pMal-hmivb plasmids on 1% agarose after digest with KasΙ. Each 
plasmid preparation was loaded on two lanes, displaying uncut (u) and cut (c).   
Correct plasmids pMal-hm and pMal-hmivb, verified by sequencing, were freshly 
transformed into E. coli NM522 and stored as glycerin cultures at -80°C. Growth and 
expression was analyzed in noseflask experiments 
4.2.2 Growth and expression of E. coli NM522 (pMal-hm)  
The experiment was carried out in noseflasks containing 30ml LB and ampicillin 
(100µg/ml). Four clones of E. coli NM522 (pMal-hm) plus one with the backbone plasmid 
pMalp2x were tested. To evaluate possible effects of recombinant protein expression on 
the cell viability and to verify expression of the recombinant protein, periodic sample 
were taken for western blot analysis, cfu determination and OD measurements according 
to 6.3.3.  
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Expression of the recombinant protein MBP-hm of the vector pMal-hm was induced by 
addition of 0.2mM IPTG when the cultures reached an OD600 of about 0.15-0.2. Growth 
diagram in Fig 4-38 shows that expression of the fusion protein had no negative effect on 
cell growth in OD as well as in cfu. Sample preparation for WB was done under non 
reducing conditions to conserve the disulfide bridging of hm. Breakage of bacteria was 
done via freeze and thaw treatment and resuspension in non reducing lysis bufferΙ 
(6.2.4.3.2) . Successful breakage was first confirmed by detection of cytoplasmic MBP 
proteins with αMBP and α rabbit IgG-HRP (not shown). The prepared samples were then 
dotted on two nitrocellulose membranes, 1µl of supernatant and a 1:10 dilution in triplets 
each. For the positive control 0.5µl purified QMW (1µg/µl) were applied (derived from 
the Medical University of Vienna). Membranes were incubated with the monoclonal 
antibody herceptin (Trastuzumab) and α human IgG-HRP, in parallel with the isotype 
control Rituximab and αhuman IgG-HRP.  Dot blot analysis showed binding of herceptin 
with the positive control but no reaction with the E. coli NM522 (pMal-hm) samples (Fig 
4-39). Analysis with the isotype control Rituximab (no positive control was available) 
showed a weak signal for clone 3 (Fig 4-40 3F). For clone 4 one dot of 6 seemed to react 
weakly positive (Fig 4-39 4F). The dot blot was repeated at the Medical University of 
Vienna but again herceptin showed no specific binding to MBP-hm (not shown). 
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Fig 4-38 Growth curve of E. coli NM522 (pMal-hm) and control E. coli NM522 (pMalp2x). Recombinant 
protein expression induced by 2mM IPTG shows no negative effect on growth. 
 
Fig 4-39 Dot blot analysis of whole cell protein extract of E. coli NM522 (pMal-hm). Cone 1, 2, 3 and 4 
before induction of recombinant MBP-hm expression (A) and after 150 min (F). p2x: NM522 (pMalp2x) 
negative control. QMW: positive control. The presence of the hm portion of the fusion protein was 
examined with the monoclonal antibody herceptin and αhuman IgG-HRP. 
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Fig 4-40 Dot blot analysis of whole cell protein extract of E. coli NM522 (pMal-hm). Clone 1, 2, 3 and 4 
before induction of recombinant MBP-hm expression (A) and after 150 min (F). p2x: NM522 (pMalp2x) 
negative control. QMW: isotype control. The presence of the hm portion of the fusion protein was 
examined with the isotype control Rituximab and αhuman IgG-HRP. 
As dot blot analysis failed to clearly show hm expression it was decided to go for a native 
PAGE. Electrophoretic separation could facilitate greater accessibility to the mimotope, 
which could be hidden in the whole cell protein extract in dot blot analysis. In native 
PAGE proteins are not covered by negative charges, provided from the dye, which are 
proportional to their protein mass like in SDS PAGE.  Mobility of proteins in native PAGE 
depends on the intrinsic charge of the proteins. Proteins are under non-reducing and non-
denaturing conditions retaining their native structure. Samples from E. coli NM522 (pMal-
hm) c 3 and c2 were run on a gel, blotted onto a nitrocellulose membrane and detected 
with αMBP and αrabbit IgG-HRP. As shown in Fig 4-41 MBP is negatively charged and can 
be detected via native PAGE. From this it was assumed that MBP-hm is also detectable 
with the specific antibody herceptin at the size of the naturally occurring E. coli MBP, as 
the small hm-fusion portion should not add a big difference in charge.  But a native PAGE 
and subsequent examination of the membrane with herceptin and αhuman IgG-HRP 
showed no signal. Also incubation of the membranes of native and SDS-Pages with ROTI-
REFOLD (Carl Roth GmbH, Karlsruhe, Germany) trying to renature the protein before 
incubation with Trastuzumab, showed no hm detection. A standard WB and detection 
with αMBP and αrabbit IgG-HRP was performed, to prove if the size difference between 
E. coli MBP (∼41kDa) and the recombinant MBP-hm (∼45kDa) of about 4kDa can be 
detected on WB. Just for clone 3, 120 min after induction of expression a band emerges 
at about the expected size (Fig 4-42 3E). It is nearly overlapping with the E. coli MBP and 
could as well be a breakdown product of the fusion protein (Fig 4-42). Therefore, 
detection of MBP-hm using αMBP antibodies is not applicable for standard WBs. 
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Fig 4-41 WB analysis (10% native PAGE) of whole cell protein extract of E. coli NM522 (pMal-hm) c2 and c3. 
F: 150 min after induction of recombinant protein expression. The presence of the MBP portion was 
examined with αMBP and αrabbit IgG-HRP. 
 
Fig 4-42 WB analysis (10% SDS PAGE) of whole cell protein extract of E. coli NM522 (pMal-hm) c3 and c4. +:  
E. coli NM522 (pMalp2x) E: 120 min and B: 30min after induction of recombinant protein expression. The 
presence of the MBP portion was examined with αMBP and α rabbit IgG-HRP.
 
4.2.3 Growth and expression of E. coli PC2133 (pMal-p2x), E. coli NM522 (pMal-hm), E. 
coli W3110 (pMal-hm) and E. coli PC1363 (pMal-hm)  
With new transformed strains of E. coli PC2133 (pMal-p2x), E. coli NM522 (pMal-hm), E. 
coli W3110 (pMal-hm) and E. coli PC1363 (pMal-hm) noseflask experiments were 
performed. The intension was to check whether the expression varies in different strains 
leading to better hm expression, and to test more clones in general. Further hm 
expression should be monitored in course of time. 
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The experiments were carried out in noseflasks containing 30ml LB and ampicillin 
(100µg/ml). E. coli strains with the plasmid pMal-hm and with the backbone plasmid 
pMalp2x as control were tested. Periodic samples were taken for western blot analysis, 
cfu determination and OD measurements according to 6.3.3. Expression of the 
recombinant proteins MBP-hm/recombinant MBP of the vector pMal-hm/pMalp2x was 
induced by addition of 0.2mM IPTG when the cultures reached an OD600 of about 0.15-
0.2.  
4.2.3.1 E. coli PC2133 
E. coli PC2133 was supposed to be ΔmalE. A strain devoided of E. coli MBP would offer 
valuable clues to recombinant MBP protein expression and detection. PC2133 was 
transformed with the backbone plasmid pMal-p2x to see if the western blot analysis 
would allow clear identification of MBP-hm without an interfering band of E. coli MBP at 
about 40-42kDa. A growth study was performed (Fig 4-43) and periodic sample were 
processed for SDS-PAGE and subsequent western blot analysis (Fig 4-44). As expected the 
addition of IPTG had no negative effect on cell growth in OD as well as in cfu. E. coli strain 
PC2133 exhibits besides the recombinant MBP (∼51kDa) the E. coli MBP band at about 
40kDa, seen in samples before IPTG addition (Fig 4-44 A), and therefore shows no 
advantage over the standard lab strains for detection of recombinant MBP fusion 
proteins.  
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Fig 4-43 Growth curve of E. coli PC2133 (pMalp2x). Recombinant protein expression was induced by 
addition of 2mM IPTG. 
 
Fig 4-44 WB analysis (15% SDS PAGE) of whole cell protein extract of E. coli PC2133 (pMalp2x) c1, c2 and c3. 
+:  E. coli NM522 (pMalp2x) A:  time point of induction, B: 30min and C: 60 min after induction of protein 
expression. The presence of the MBP portion was examined with αMBP and α rabbit IgG-HRP. E. coli MBP 
appears at about 41 kDa. 
4.2.3.2 Growth curve of E. coli PC1363 (pMal-hm), E. coli NM522 (pMal-hm) and E. coli 
W3110 (pMal-hm) 
Growth and expression experiments of different E. coli strains harboring plasmid pMal-
hm were performed showing similar growth behavior for all tested strains (Fig 4-45, Fig 
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4-46, Fig 4-47). Addition of IPTG had no negative effect on cell growth in OD as well as in 
cfu. 
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Fig 4-45 Growth curve of E. coli NM522 (pMal-hm). Recombinant protein expression was induced by 
addition of 2mM IPTG. 
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Fig 4-46 Growth curve of E. coli PC1363 (pMal-hm). Recombinant protein expression was induced by 
addition of 2mM IPTG. 
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Fig 4-47 Growth curve of E. coli W3110 (pMal-hm). Recombinant protein expression was induced by 
addition of 2mM IPTG.  
4.2.3.3 Western blot analysis of E. coli NM522 (pMal-hm), E. coli PC 1363 (pMal-hm), 
and E. coli W3110 (pMal-hm) 
Analysis of protein samples from growth and expression studies of different strains 
harboring plasmid pMal-hm did not result in an ambiguously detection of MBP-hm in WB 
analysis. A bulky band that shows up at ∼40-43kDa throughout all western blot analyses 
might be E. coli MBP as well as the breakdown product MBP*. WB analysis of protein 
samples from E. coli NM522 (pMal-hm) in Fig 4-48, E. coli W3110 (pMal-hm) in Fig 4-49, E. 
coli PC1363 (pMal-hm) in Fig 4-50 and combined in one blot in Fig 4-51 show for 
individual clones a faint band at the anticipated molecular weight of the target protein. 
This is for E. coli PC1363 (pMal-hm) c2 in Fig 4-50, E. coli PC1363 (pMal-hm) c1 in Fig 4-51 
and after 180 min expression E. coli NM522 (pMal-hm) c3 in Fig 4-52. In WB analysis 
shown below (Fig 4-48, Fig 4-49, Fig 4-50, Fig 4-51, Fig 4-52) sample A, taken before IPTG 
induction, shows neither a band for the E. coli MBP at ∼ 41kDa nor for the recombinant 
MBPs at ∼45kDa. This is attributed to addition of glucose to the overnight cultures which 
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represses not only recombinant MBP expression but also blocks the transcription malT 
and therefore the malT dependent gene malE.   
 
Fig 4-48 WB analysis (15% SDS PAGE) of whole cell protein extract of E. coli NM522 (pMal-hm) c1 and c2. +:  
E. coli NM522 (pMalp2x) A:  time point before induction; B: 30 min, C: 60 min, D: 90 min, E 120 min and F: 
150 min after induction of recombinant protein expression. The presence of the MBP portion was examined 
with αMBP-HRP and α rabbit IgG-HRP.  
 
 
Fig 4-49 WB analysis (15% SDS PAGE) of whole cell protein extract of E. coli W3110 (pMal-hm) c1 and c2. +:  
E. coli NM522 (pMalp2x)  A:  time point before induction; B: 30 min, C: 60 min, D: 90 min, E 120 min and F: 
150 min after induction of recombinant protein expression. The presence of the MBP portion was examined 
with αMBP and α rabbit IgG-HRP.  
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Fig 4-50 WB analysis (15% SDS PAGE) of whole cell protein extract of E. coli PC1363 (pMal-hm) c2 and c3. +:  
E. coli NM522 (pMalp2x)  A:  time point before induction; B: 30 min, C: 60 min, D: 90 min, E 120 min and F: 
150 min after induction of recombinant protein expression. The presence of the MBP portion was examined 
with αMBP and α rabbit IgG-HRP. ∗) c2 shows a weak band appearing at the expected size of MBP-hm 
(∼45kDa) 
 
 
 
Fig 4-51 WB analysis (15% SDS PAGE) of whole cell protein extract of E. coli PC1363 (pMal-hm) c1, E. coli 
W3110 (pMal-hm) c1 and E. coli NM522 (pMal-hm) c1, c2 and c3. +:  E. coli NM522 (pMalp2x) A:  time point 
before induction; B: 30 min, C: 60 min, D: 90 min, E 120 min, F: 150 and G: 180 min after induction of 
recombinant protein expression. The presence of the MBP portion was examined with αMBP-HRP and α 
rabbit IgG-HRP. ∗) c1 shows a weak band appearing at the expected size of MBP-hm (∼45kDa). 
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Fig 4-52 WB analysis (15% SDS PAGE) of whole cell protein extract of E. coli NM522 (pMal-hm) c3. +:  E. coli 
NM522 (pMalp2x) with MBP at about 51kDa A:  time point before induction; B: 30 min, C: 60 min, D: 90 
min, E 120 min, F: 150 min and G 180 min after induction of recombinant protein expression. The presence 
of the MBP portion was examined with αMBP and α rabbit IgG-HRP.  ∗) c3 shows a weak band appearing at 
the expected size of MBP-hm (∼45kDa 
4.2.3.4 Growth and expression of E. coli NM522 (pMal-hm) and NM522 (pMal-hmivb) 
Additionally new transformed clones NM522 (pMal-hm) and NM522 (pMal-hmivb) were 
included and the experiment was carried out as given in 4.2.2. Growth diagram shows 
that expression induction of the fusion protein had no negative effect on cell growth in 
OD (Fig 4-53) (no cfu values were determined). In this experiment cell breakage for WB 
samples was done via osmotic shock treatment and resuspension in lysis bufferΙΙΙ 
(6.2.4.3.2), including EDTA to inhibit proteases and lysozyme. In addition the ivb-portion 
might guard the peptide from degradation. No signal was detected in WB analysis after 
membrane development with herceptin and anti human IgG-HRP (not shown). 
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Fig 4-53 Growth curve of E. coli NM522 (pMal-hm) and E. coli NM522 (pMal-hmivb). Recombinant protein 
expression was induced by addition of 2mM IPTG. 
4.2.4 Cell fractionation of E. coli NM522 (pMal-hm) 
The cellular location and solubility of the target protein was analyzed in different cell 
fractions: total cell protein (TCP), media sample (M), periplasmic fraction (P) and soluble 
cytoplasmic fraction (C). An insoluble fraction was not further processed.  
The experiment was carried out in an Erlenmeyer flask containing 60 ml LB and ampicillin 
(100µg/ml), inoculated with E. coli NM522 (pMal-hm). As the culture reached an OD600 of 
0.15, it was split into two flasks, each 30 ml. One flask was induced by adding IPTG 
(2mM), the other flask served as a control (uninduced). After reaching an OD600 of 0.7, 
cultures were spinned down in SS34 tubes at 4°C, 6500g 15 min and further treated as 
given in 6.2.7 to get different cell fractions. 
Normalized volume of cell fractions for loading a 15% SDS PAGE is given in Tab 4-5. Fig 
4-54 shows the cell fraction proteins of induced (i) and uninduced (ui) culture samples 
separated on the SDS PAGE and developed using αMBP and αrabbit IgG-HRP.  Ui samples 
exhibit a band at about 40kDa which is expected for E. coli MBP. No big difference is 
visible in ui and i samples. No bands were detected in the M fraction. The TCP samples 
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show two bands, one at ∼40kDa and a second at ∼43kDa. The same bands are visible in P 
fraction. The C samples show the same bands in lower concentrations and additional 
bigger bands are visible in the C fraction of i samples. The band at about 43kDa was not 
expected, since it would either be related to unprocessed E. coli MBP, which would not 
show up in PP, or to MBP*, which should just appear in induced samples. One possible 
explanation could be that the fusion protein is produced when not repressed by glucose 
during growth, and therefore a breakdown product can be detected. A faint band at 
about 47kDa shows up, which could be related to the unprocessed MBP-hm, and bands 
above 80 and 150 kDa. The 80 kDa band is also slightly visible in P fraction of i sample. 
These bands are supposed to be multimers of MBP-hm proteins. Occasionally multimers 
of a fusion protein can be observed, mostly due to disulfide bonds that were not 
adequately reduced before loading the gel. This experiment was performed to gain 
insight into the recombinant protein localization but has to be repeated to deduce 
reliable information. The TCP fraction should display all bands visible in P, C and M, which 
was not observed. 
 
 
Tab 4-5 Determination of the normalized sample volumes to load on a standard 15-well mini SDS-PAGE gel. 
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Fig 4-54 15% SDS-PAGE of induced (i) and uninduced (ui) culture of E. coli NM522 (pMal-hm). Different cell 
fractions were analyzed: TCP total cell protein, M media sample, P periplasmic fraction, C soluble 
cytoplasmic fraction 
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5. Discussion  
The aim of this work was to adopt the Bacterial Ghosts system as candidate for delivery of 
tumor peptide antigens. Therefore putative B-cell epitope mimics of the tumor antigen 
Her-2/neu, which already showed tumor growth inhibition [31, 55], were introduced in 
the system, intending to design a therapeutic anti cancer vaccine with preventive long 
term immunity against breast cancer. 
One part of this work dealed with three linear epitopes, p4, p6 and p7, which were fused 
and as a multiepitope successfully cloned into the pMal-p2x expression system, directing 
the epitopes as a MBP fusion protein to the periplasm of E. coli. The results in this work 
demonstrate detection of the epitopes with p467 specific immune sera in western blot 
analysis, and showed that produced BGs are carrying p467. In mice immunization 
experiments a significant higher titer of elicited antibodies of the experimental groups 
versus control group showed the effective delivery of p4, 6 and 7 by BGs. 
The second part of this work was to express a circularized conformational mimotope, 
herceptin mimotope (hm), in the same expression system pMal-p2x. Especially for the 
hm, transport and subsequent disulfide bridging in the PPS is essential, as conformational 
accuracy is required for immunogenicity. Although cloning succeeded and sequencing of 
the vector showed the hm in the correct reading frame, detection with the monoclonal 
antibody Trastuzumab was not successful. 
5.1 Multiepitope p467 
Initial attempts in cloning p467 presented some difficulties. The 194 bp p467 sequence 
had to be constructed by ourselves, as no DNA template was provided. Peptide 
sequences of the single linear epitopes, which were successfully tested in preliminary 
experiments at the Medical University of Vienna, were translated into DNA, considering 
the E. coli codon usage. When designing the multiepitope, the three single epitope 
sequences were coupled with restriction sites to remain flexible for using just one or two 
parts of it, or using it in different expression systems later on. Linker sequences were 
inserted, consisting of glycine amino acids, so that the protein domains are free to move 
and do not sterically interfere with one another.  
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The sequence was ordered, like primers, as ssDNA at VBC Genomics (Vienna, Austria). 
DNA accuracy is guaranteed up to 120bp maximum, so the whole 194 bp sequence was 
planned to be produced by PCR in two parts in multistep reactions. An overview is given 
in Fig 4-5 and Fig 4-6. Several attempts to produce the p467 fragment fail presumably due 
to formation of secondary structures during PCR. Sequencing of “positive” clones always 
indicated some mismatch regions and base deletions. It could have been tried to solve 
these problems by using single strand binding proteins like T4 Gen 32 protein, which have 
been reported to increase the specificity of PCR reactions [58], but as a lot of time had 
been spent on PCR and clone testing, it was decided to order the sequence at GenArt 
(Regensburg, Germany). The synthetic gene was delivered incorporated into a cloning 
vector with an attached sequence protocol; the p467 sequence was cut out, cloned into 
vector pMal-p2x and the vector pMal-467 was amplified in E. coli NM522 within a short 
period of time.  
The first growth and expression experiments in E. coli NM522 showed that expression of 
the MBP-467 fusion protein did not impair growth (Fig 4-12). Western blot analysis of the 
whole cell protein extract and detection with αMBP antibodies revealed that the fusion 
protein is stable at least for 120 min without degradation (Fig 4-13). Cotransformation of 
pMAL-467 and the lysis plasmid pGLysivb and subsequent lysis studies of 5 clones 
achieved LEs of up to 99.9%. The whole cell protein extract of the BGs was checked with 
p467 specific mouse, rabbit and purified rabbit antiserum in WB analysis exhibiting a 
clearly recognizable fusion protein band at about 57kDa for all sera, which is absent prior 
expression induction (Fig 4-16, Fig 4-17, Fig 4-18). The same pattern shows up at about 
50kDa, which is most likely a truncated form of the fusion protein produced by 
proteolysis, but still recognized by p467 antiserum. In several WBs the mouse serum has 
shown the least amount of unspecific bands and therefore lowest background signals. 
The final BG-p467 production step was done in a 20.0l low density batch fermentation 
using a 30l Techfors-S fermenter (Infors-HT). Online process data were monitored by the 
IRIS software (Infors-HT) and displayed an oxygen increase immediately after induction of 
expression (Fig 4-19). Generally the increase of oxygen in the media during cultivation 
goes along with cell death and is expected after LI, as bacteria are no longer consuming 
oxygen. Although earlier studies proved no negative effect for this fusion protein 
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expression on cell viability, oxygen increased when protein expression was induced 60 
min before lysis induction. Reduction of viability during 60 min of recombinant protein 
expression was 42, 08%. This value needs to be viewed critically since it is received from 
agar plates that were incubated over night and could therefore be attributed to a long 
term effect of MBP-467 on bacteria. Ideal fermentation conditions may lead to a higher 
rate of recombinant protein production having a toxic long term effect on bacteria not 
seen for bacteria grown in noseflasks under suboptimal growth condition without pH and 
oxygen level regulation. Stagnation in growth due to increased recombinant protein 
production together with simultaneously increased stirring rate could both contribute to 
the accumulation of dissolved oxygen in the culture broth after IPTG induction. Thirty min 
of LI resulted in a significant decrease in cfu giving a total killing of 98.69%. After 60 min 
lysis the cfu values dropped below the counting range which gives reliable data to make 
extrapolations for the used sample dilutions. When using the lowest detection limit as a 
virtual value calculation of LE results in >99.76%. The fact that microscopy showed almost 
exclusively BGs after LI confirms the presumption that E-mediated lysis produced 
successfully BGs, and cell death observed before LI occurred due to a long term effect on 
plates, as E-mediated lysis depends on specific functions of the cell division machinery of 
a viable culture [59]. Western blot analysis of lyophilized BG-p467 samples using p467 
mouse antiserum showed a strong band at about 57kDa (Fig 4-23) and samples taken 
during fermentation present the accumulation of protein E after LI and the decrease of 
cytosolic BCCP, indicating E-mediated lysis.  
No quantification of the pMal-467 fusion protein was performed in this study. Recent 
studies using PPS expression of foreign proteins in BGs reached 200ng recombinant PorB 
and 340ng recombinant MOMP/µg lyophilized BGs [60]. Sterility of lyophilized p467-BGs 
was confirmed and the final product was handed over to the Department of 
Pathophysiology at the Medical University of Vienna (Austria) for animal experiments. 
Immunization of BALB/c mice was done through subcutaneous injection with different 
p467-BG concentrations and resulted in induction of peptide specific antibodies (Fig 4-25, 
Fig 4-26, Fig 4-27). The slight increase in titers of the control group could be due to the 
unspecific binding of antibodies to BG components, but the significant higher titers of the 
test groups show that BG mediated delivery of p467 induces successfully peptide specific 
IgG antibodies (Fig 4-25, Fig 4-26, Fig 4-27). But compared to other systems, like TT- and 
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virosom-conjugates, the titer was rather low according to the first partial report (just 
limited information was available, therefore no precise numbers can be offered). The 
proliferation of spleen cells was measured by H
3
 thymidin incorporation. In vitro 
stimulation with BG-467 peptides did not lead to increased proliferation. IFN-gamma 
measurements of the supernatants using ELISA did not show an increase of IFN-gamma 
production after in vitro stimulation with BG-467 peptides. These results were similar to 
the TT-and virosom-conjugate data. Even only limited results are available at the moment 
in general it can be concluded that the results correspond to earlier data and confirm the 
hypothesis, that the used Her-2/neu sequences display B-cell epitopes and therefore do 
not trigger T-cell response themselves. Also a combination of B-cell and T-cell epitopes 
could be advantageous, which could be easily combined in the BG system. This should 
allow determining the advantages of BG-467 as a therapeutic cancer vaccine in 
comparison to TT- or virosom-conjugates delivered p4, p6 and p7 antigens. 
5.2 Herceptin mimotope 
Cloning of the herceptin mimotope (hm) into pMal-p2x involved E. coli codon 
optimization and insertion of a linker peptide between MBP and hm. Therefore a glycine-
proline linker was used to separate the epitope from the residual fusion partner and to 
allow protein tertiary structure formation by disulfide bridging in the periplasm. The 69bp 
fragment was ordered as ssDNA sense and antisense at VBC Genomics (Vienna, Austria).  
Sequence verified clones of E. coli NM522 (pMal-hm) were analyzed in growth and 
expression experiments. The production of the MBP-hm fusion protein did not impede 
growth (Fig 4-38). Cell disruption as well as detection of the fusion protein by the 
monoclonal antibody Trastuzumab had to be done under non denaturing conditions to 
preserve the native structure to ensure antibody binding. Cell disruption was done using 
the freeze/thaw method [61] to release recombinant proteins. Effective cell breakage was 
first confirmed by αMBP detection and afterwards specific detection of the native 
conformation with Trastuzumab was performed, but could not be proved in dot blots (Fig 
4-39). Therefore it was decided to conduct protein separation by native page, which could 
gain access to the mimotope, that otherwise might be hidden in the whole cell protein 
extract. As in native PAGE proteins are not covered by negative charges the migration is 
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therefore not corresponding to protein mass like in SDS PAGE. The intrinsic charge of 
MBP/MBP-hm had to be explored first by detection of the MBP portion of the fusion 
protein with αMBP. WB analysis showed that MBP was negatively charged and could be 
detected on nitrocellulose membranes after native PAGE runs. A weaker band, probably 
MBP-hm, is seen next to a dominant band, which was supposed to be the E. coli MBP 
or/and a breakdown product, respectively (Fig 4-41).  Assuming that the small hm portion 
is not adding a big difference in charge (molecular weight of hm is a tenth of MBP) 
suggests that the fusion protein should be detectable next to the E. coli MBP and may 
therefore be visible as the weaker band in Fig 4-41. But a native PAGE performed under 
the same conditions, blotted to a nitrocellulose membrane and detected by Trastuzumab 
produced no positive signal for the recombinant MBP-hm.  
Growth and expression tests were extended to additional E. coli strains. Different clones 
of newly transformed E. coli NM522 (pMal-hm), E. coli W3110 (pMal-hm) and E. coli 
PC1363 (pMal-hm) were checked to see whether the expression varies in different strains 
and may lead to better expression in one of them. Protein samples were analyzed by SDS-
PAGE separation and subsequent western blot analysis detecting the MBP portion of the 
fusion protein. The intension was to estimate the time point of detectable protein 
expression start on the blot, the amount of full length protein compared to degradation 
products production and the time frame in which the fusion protein is stable and 
detectable. For only two clones of E. coli PC1363 and one clone of E. coli NM522 a faint 
band could be assigned to MBP-hm, located slightly above the dominant band, which is 
supposed to be the E. coli MBP at about 40-42kDa (Fig 4-50, Fig 4-51, Fig 4-52). This weak 
band MBP-hm shows up at about 90 min after protein induction and is thereafter stable, 
or at least in a balance between production and proteolysis. A dot blot analysis for these 
studies was performed to explore the native conformation of MBP-hm. Cell breakage was 
done by osmotic shock this time, because it might be “more gentle” than freezing and 
thawing, but incubating the membrane with Trastuzumab revealed no signal specific for 
hm.  
 According to the protocol for “expression of recombinant proteins by fusion to the 
maltose binding protein” [53] there could be two possible explanations for a breakdown 
product of the fusion protein. One is translation termination, if the protein of interest is in 
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the wrong translational reading frame, the other is proteolytic cleavage due to protein 
instability, whereby in this case mostly a small amount of full length protein can be seen. 
As sequencing confirmed the fusion protein to be in the right reading frame, the 
accumulation of E. coli MBP and the breakdown product of the MBP-hm fusion protein at 
40-42kDa giving together the detected bulky band is most likely. The fact that this 
dominant band mostly does not show up before induction of protein expression does not 
necessarily mean that it is solely the recombinant protein but may be due to the addition 
of glucose to the overnight cultures. When cells are growing under high glucose 
concentrations the transport of glucose via the phosphotranferase system exerts strong 
catabolite repression which blocks the transcription of malT and the malT-dependent 
genes of the malK lamb malM and malE malF malG operons of the E. coli chromosome 
[62]. In expression analysis of this work missing the addition of glucose to the overnight 
culture (Fig 4-44), E. coli MBP was detected before IPTG induction resulting from 
endogenous synthesis of the inducer. The uninduced level of E. coli mal gene expression 
seems to be a preparation for the arrival of the “true” substrate by endogenous 
induction, geared for the scavenging of low levels of maltose and maltodextrins [62, 63]. 
The oxidizing environment of the PP contributes to the formation and rearrangement of 
disulfide bonds [64] and is therefore an attractive destination for recombinant eukaryotic 
proteins. For transport to the PP the MBP was found to display an effective solubilizing 
partner inhibiting misfolding and exerting benefits during and after folding [65]. Transport 
to the periplasm often leads to proper folding and thus to a more stable fusion protein, 
but this was not observed in this work for pMal-hm. Mostly proteins are unstable because 
they do not fold properly, this is particularly true for proteins with disulfide bonds [53]. 
Continuative work should therefore go along with using different protease negative 
strains as well as trying several methods for non denaturing cell disruption as for many 
unstable proteins most of the degradation happens during harvest and cell breakage. In 
addition, using malE negative strains would give more precise information about the 
dominant band at 40-42kDa; to which extent it is really related to a breakdown product of 
the MBP-hm fusion protein or if it is solely E. coli MBP. It would also be useful to try co-
overproduction of protein disulfide isomerases, praticularly DsbC, which has been shown 
to greatly improve proper disulfide bond formation [66]. 
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In general it has to be noted that some inaccuracies regarding the detected protein sizes 
in WB analysis were observed in this work. In Tab 4-1 and Tab 4-4 the protein sizes of E. 
coli MBP and all MBP-fusions are listed with and without signal peptide. Usually, the 
signal peptide is cleaved off by the cell’s secretion apparatus [67] during transport action 
through the cytoplasmic membrane. In WB analysis of this work often protein bands at 
the size of the precursor fusion protein including the SS were detected, giving in case of 
MBP-467 a band at ∼57kDa instead of ∼54kDa. This could be due to imprecise size 
separation of proteins in SDS-PAGE, but also due to the high rate of recombinant protein 
production. Overproduction often leads to only partial processing of the recombinant 
protein, retaining the leader peptide after transport to the PPS [68]. Therefore detection 
of a precursor protein does not have to mean that transport to the PP was not successful. 
By increasing the expression of the signal peptidase Ι, which is responsible for cleaving 
the SS of MBP, the rate of processed proteins might be increased. However, cleavage is 
not necessary to accomplish transport to the PP and BGs devoiding their cytoplasmic 
content after lysis have been shown to comprise the MBP-467 fusion protein proving 
thereby the periplasmic location of the MBP-467. 
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6. Material and methods 
6.1 Material 
6.1.1 Chemicals 
Chemicals, media, solutions and buffers are purchased from Merck (Darmstadt, Germany) 
and Roth (Carl ROTH, Karlsruhe, Germany). 
6.1.2 Buffers and solutions 
0,5M EDTA 186g EDTA 
800mL dH2O 
pH 8 with NaOH 
 
Ethidium Bromide 10mg/ml 
 
0,2g Ethidium bromide 
to 20mL with dH2O 
 
1M Tris 
 
1M Tris 
121,1g Tris 
to 800mL with H2O 
cool to room temperature 
desired pH with HCl 
 
MOPS I 
 
100mM MOPS 
10mM CaCl2 
10mM RbCl2 
with KOH to pH 7 
 
 
 
MOPS II 100mM MOPS 
70mM CaCl2 
with KOH to pH 6,5 
 
1% and 2 % Agarose 3g (or 6g) Agarose 
6mL 50x TAE buffer 
294mL dH2O 
 
50x TAE 2M Tris 
1M CH3COOH 
0,1M EDTA pH 8,2 
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10x PBS 137mM NaCl 
2.7mM KCl 
10 mM Na2HPO4 
2 mM KH2PO4 
800mL dH2O 
pH 7,4 with HCl 
fill up to 1L with dH2O 
 
50% Glycerol 25ml 100% glycerol 
 25ml ddH2O 
 mix and autoclave 
 
0,85% Saline  
Medium  
8,5g NaCl 
1l ddH2O 
filled into eprouvettes 9 ml and 9,9 ml using a dispenser  
and autoclave 
 
1xNuPage®  
Sample Buffer 
6,5ml PBS  
2,5ml NuPage® LDS Sample Buffer (4x)  
1ml NuPage® Reducing Agent (10x)  
 
1xNuPage® MES  
Running Buffer 
50ml NuPage® MES Buffer (20x)  
950ml deionized water  
 
 
1x Transfer Buffer  50ml NuPage® Transfer Buffer (20x) 
100ml Methanol  
850ml deionized water  
 
1x Blocking Solution  3ml Roth Roti-Block (10x)  
27ml deionized water  
 
 
1x TBS 100ml TBS (10x, ROTH)  
900ml deionized water 
 
 
1x TBST 100ml TBST (10x, ROTH)  
900ml deionized water 
 
 
PonceauS 0,2g PonceauS  
3,0g trichloric acetic acid  
100ml ddH2O 
 
  
72 
 
Laemmli buffer 4% SDS 
20% glycerin 
10% mercaptoethanol 
0.004% bromophenol blue 
0.125 MTris HCl 
6.1.3 Plasmids 
Name Size(nt) Origin Resistance Reference Specification 
pMalp2x 6721 MB1 amp 
New England 
Biolabs Inc 
Backbone Plasmid 
pMal-ivb 6769 MB1 amp [54] Backbone Plasmid 
pGLysivb 6201 Rep gent [69] Lysis Plasmid 
pMal-467 6829 MB1 amp this work Expression Plasmid 
pMal-467ivb 6877 MB1 amp this work Expression Plasmid 
pMal-hm 6772 MB1 amp this work Expression Plasmid 
pMal-hmivb 6814 MB1 amp this work Expression Plasmid 
6.1.4 Bacterial Strains 
Escherichia coli K12 NM522 sup E thi-1Δ(Lac-proAB)Δ(mcrB-hsdSM) 5(rK
-
mK
-
) 
(F’proABlacIqZΔM15) (source: Stratagene, Heidelberg, Germany) 
Escherichia coli K12 W3110 Ion
-
 lΔ
-
F
-
mcrA mcrB IN(rrnD – rrnE) 1; (source: Lab Stock) 
Escherichia coli K12 PC1363 – (pheA) (source: Phabagen Collection, University of Utrecht, 
The Netherlands) 
Escherichia coli K12 PC2133 (source: Angela Witte, Department of Microbiology and 
Genetics, University of Vienna, Austria) 
6.1.5 Markers 
PAGE Ruler™ Unstained Protein Ladder, Fermentas (St. Leon-Rot, Germany) 
Protein Molecular Weight Marker, Fermentas (St. Leon-Rot, Germany) 
GeneRuler™ 50bp DNA Ladder, Fermentas (St. Leon-Rot, Germany) 
GeneRuler™ 1kb DNA Ladder, Fermentas (St. Leon-Rot, Germany) 
73 
 
6.1.6 Enzymes 
All enzymes are purchased from New England Biolabs (Hitchin, UK) and Fermentas Life 
Sciences (St. Leon-Rot, Germany). Double digests are performed according to the 
manufacturer’s instructions. 
6.1.7 Antibodies 
Antibodies are diluted in 1xTBS/0.3%BSA/0.05%NaN3, can be reused and stored at +4°C, 
except Streptavidin HRP, which is diluted in just 1xTSB and is not reused. .  
Primary antibody Species type Application Specificity Source  
α-MBP  rabbit 0.1-1µg ml
-1 
MBP NEB 
Mouse α p467 immune 
serum 
mouse 1:100-1:500 P467 MUW 
Rabbit α p467 immune 
serum 
rabbit 1:100 P467 MUW 
Purified rabbit α p467 
serum 
rabbit 1:20-1:50 P467 MUW 
Streptavidin HRP n/a 0.2- 0.05µg ml
-1 
Eivb, BCCP Invitrogen  
Herceptin/Trastuzumab n/a 0.1µg/ml 
Herceptin 
mimotope/QMW 
MUW 
Rituximab n/a 0.1µg/ml QYN MUW 
NEB (New England Biolabs, Hitchin, UK) 
MUW (Medical University of Vienna, Vienna, Austria, Department of Pathophysiology) 
Invitrogen (Carlsbad, California) 
secondary antibody Species type Application Specificity Source  
α human IgG HRP n/a 1:8000 herceptin MUW 
α-rabbit IgG HRP n/a 1:20000 rabbit IgG n/a 
α-mouse IgG HRP rabbit 1:3000 mouse IgG n/a 
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6.1.8 Antibiotics 
Antibiotics stocks are prepared and stored for long term at -20°C, when in use they are 
kept on 4°C 
Name Stock [mg/ml] Final concentration [µg/ml] 
Gentamycin 10 20 
Ampicillin 50 100 
6.2 Microbiological methods 
6.2.1 Isolation of plasmid DNA  
Isolation of plasmid DNA is done with Plasmid Miniprep Kit I from PEQLAB (Erlangen, 
Germany)  
6.2.2 Restriction digest and ligation 
Sequence specific cleavage 
All restriction digests are performed according to the manufacturer’s instructions. 
Ligation 
Ligations are performed with T4 ligase and corresponding buffer from New England 
Biolabs (Hitchin, UK) according to the manufacturer’s instruction. Ligation was done over 
night at 16°C. 
6.2.3 Agarose gel electrophoresis 
DNA fragments are separated on 1% and 2% agarose gels [70] depending on their size, 
using voltage from 120 – 180 and 1xTAE for running buffer. Staining of gels is done with 
ethidium bromide (1µg/ml), visualization via UV light (250nm) by ChemiDoc™ XRS (Bio-
Rad, Hempstead, UK) using the software QuantityOne (Bio-Rad, Hempstead, UK). 
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6.2.4 Polyacrylamid Gel Electrophoresis (PAGE) 
6.2.4.1 Standard SDS Acrylamidgel 
6.2.4.1.1 Gel preparation 
Preparation of SDS – gels are done according to [71]. Stacking gel contains 4% and 
separation gel 8 – 15 % acrylamid, according to protein size. Polymerization is done with 
TEMED and 10% (w/v) APS. 
6.2.4.1.2 Sample preparation 
Pellets of 1ml culture samples were resuspended in 1xTBS according to their OD600 
(OD600 x 250 = volume of 1xTBS in µl used for resuspension + same volume of 2x 
Laemmli-buffer. After lysis the highest OD600 value before LI is used for calculation. 
Samples are heated at +96°C for 15 min. before loading on the gel the samples have to be 
spinned down for 3 min at maximum speed. 15-20µl of the supernatant is loaded on the 
gel, 5µl of molecular weight protein marker are loaded.   
6.2.4.1.3 Gel run 
For migration into the stacking gel an initial voltage of 30V is set for 10 min and then 
increased to 100V at a maximum of 30mA. 
6.2.4.2 Precast Bis Tris Acrylamidgels 
6.2.4.2.1 Gel preparation 
Pre-Cast gels from Invitrogen (Carlsbad, California) are used (NuPAGE® Novex 12, 15%Bis-
Tris Gels) according to the manufacturer’s instructions. Equipment for electrophoresis as 
well as the buffers (1xMES running buffer) are also from Invitrogen.  
6.2.4.2.2 Sample preparation 
Pellets of 1ml culture samples were resuspended in 1x NuPage sample buffer according to 
their OD600 (OD600 value x 250 = volume of 1x NuPage sample buffer) and it is mixed well. 
After that samples are is incubated at +99°C for 10 min. The protein sample can be stored 
at -20°C or used directly. Before loading on the gel the samples have to be spinned down 
for 3 min at maximum speed. 15µl to 20µl of the supernatant is loaded on the gel, 5µl of 
molecular weight protein marker are loaded. 
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6.2.4.2.3 Gel run 
The gel is run at 180 Volt for ∼60 min. 
6.2.4.3 Native Acrylamidgel 
For native PAGE reducing and denaturizing agents were excluded as possible. 
6.2.4.3.1 Gel preparation 
10% Gel, 5ml   H2O   1.9ml 
30% Acryl amid mix 1.7ml 
1.5M Tris (pH 8.8) 1.3ml 
APS   0.05ml 
Temed   0.002ml 
Gel loading buffer  50mM Tris-Cl (pH 6.8) 
0.1% Bromephenol blue 
10% Glycerol 
1xTris glycine electrophoresis buffer 
25mM Tris 
250mM Glycin (pH 8.3) 
6.2.4.3.2 Sample preparation 
Freeze and thaw 
Disruption of bacterial cells for detection of proteins under non reducing conditions was 
done by spinning down 1ml culture sample and resuspending the pellet in 20µl 
lysisbuffer. Three cycles of freeze and thaw were performed: 10 min at -20°C and let thaw 
at room temperature. 
LysisbufferΙ:   50mM Tris HCl pH 7.5 
150mM NaCl 
Lysisbuffer ΙΙ:  50mMTrisHCl  pH  7.5 
   150mMNaCl 
   20mM EDTA 
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Osmotic shock 
Pellet of 1ml culture sample was resuspended in 1ml Lysisbuffer ΙΙΙ and left waving at 
room temperature for 10 min. After centrifugation for 10min, 10 000g at 4°C the 
supernatant was decanted. For osmotic shock the pellet was resuspended in ice-cold 
5mM MgSO4, waving on ice for 10 min. Periplasmic proteins end up in the supernatant by 
spinning down for 10min, 10 000g at +4°C. 
LysisbufferΙΙΙ:  10mg Lysozyme 
   20%w/v Saccharose 
   30mM Tris HCl  pH 8 
   1mM EDTA 
5xSample buffer 15.5 ml of 1M Tris-HCl (pH=6.8)  
2.5ml of a 1% solution of bromophenol blue; 
7.0ml of water 
25ml of glycerol 
 
6.2.4.3.3 Gel run 
The gel was run at 125V and 12mA for 6 hours. 
6.2.5 Western Blot Analysis 
6.2.5.1 Transfer of proteins 
Transfer from proteins of SDS – gels to nitrocellulose membranes is done by a Trans-Blot® 
SD Semi-Dry Electrophoretic Transfer Cell (Bio-Rad, Hempstead, UK) according to the 
manufacturer’s instruction. Transfer of pre – cast gels is done by wet blot using XCell II™ 
Blot Module from Invitrogen (Carlsbad, California) according to the manufacturer’s 
instructions. The protein transfer is verified by staining with PonceauS and the band of 
the molecular weight marker is marked with a ball pen. Blocking is carried out for 2 hours 
at room temperature or over night at +4°C, using 5% “fat-free milk powder” in 1xTBST. 
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6.2.5.2 Antibody incubation and development 
The membrane is washed 3x5 min in 1xTBST and is then incubated with the first antibody 
for 2 hours at room temperature. After incubation the membrane is washed 3x5 min in 
1xTBS. Then the second antibody (HRP-coupled) is applied for one hour and the 
membrane is washed again three times in 1xTBS. Then membranes are incubated with 
5ml SuperSignal West Pico Chemiluminescent Substrate from Pierce (now Thermo 
Scientific, Rockford, USA) for 3 min according to the manufacturer’s instructions. All steps 
are performed under agitation. Detection is done with ChemiDoc™ XRS (Bio-Rad, 
Hempstead, UK) using the software QuantityOne (Bio-Rad, Hempstead, UK).  
6.2.5.3 Stripping of PVDF membranes 
Roti®-Free Stripping-Puffer (Carl Roth, Karlsruhe, Germany) provides the opportunity to 
remove antibodies and chemiluminescence staining from WB membranes and allows 
therefore multiple detections on one membrane. All steps are performed under agitation: 
a) Used membrane is washed with 1xTBST for 20 min 
b) Incubation of 30 min with Roti®-Free Stripping-Puffer at ~ 60°C 
c) 2x20 min washed with 1xTBST 
d) 1 hour blocking in 1xTBS/ 5% fat-free milk powder 
e) Continue with antibody incubation and development 6.2.5.2 
6.2.6 Dot blot analysis 
Dilute protein samples in buffer (lysisbufferΙ - ΙΙΙ was used) to final protein 
concentrations of ∼1-100ng/µl. Apply 1µl samples directly onto nitrocellulose membrane. 
After applying the samples, the membrane is dried for at least 2 hours at room 
temperature before proceeding with the detection process. Immune-detection is done 
according to 6.2.5.2. 
6.2.7 Preparation of separated cell fractions and detection of target proteins 
Preparation of cell fractions was done according to the protocol of target protein 
verification from the pET System manual, Novagen, 8
th
edition, page 35 – 38. Following 
fractions were analyzed: total cell protein (TCP), media sample (M), periplasmic fraction 
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(P) and soluble cytoplasmic fraction (C). Fractions of culture samples were kept on ice and 
processed and analyzed in parallel. A culture sample for TCP was taken prior harvest. The 
culture was harvested and the supernatant after centrifugation yielded in the M sample 
which was TCA precipitated. The pellet was resuspended in Tris-HCl and after addition of 
EDTA gently stirred at room temperature. Centrifugation and subsequent resuspension in 
ice cold MgSO4 and stirring at room temperature released the periplasmic proteins. The P 
fraction was TCA precipitated from the supernatant after centrifugation. The pellet was 
treated with BugBuster Protein Extraction Reagent, formulated for gentle disruption of 
the cell wall, resulting in the liberation of soluble protein, the C fraction. Samples were 
normalized according to the following worksheet and loaded onto a 15% polyacrylamid 
gel. 
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6.2.8 Purification of DNA fragments after gel separation 
6.2.8.1 Elution of bands from agarose gels 
DNA purification when excised from an agarose gel is done using Gel Extraction Kit from 
Quiagen (Duesseldorf, Germany), according to the manufacturer’s instruction. 
6.2.8.2 Elution of bands from polyacrylamid gels 
a) Complete electrophoresis, staining of the gel and gel documentation (according to 
6.2.3) 
b) Excise intensely stained DNA band out of the gel  and put into one eppendorf tube 
c) Incubate for 3 hours at 37°C in 500µl elution buffer to elute DNA 
d) Centrifuge tubes at maximum speed (benchtop centrifuge) and transfer 
supernatant to a clean tube 
e) Supernatant is precipitated in 1ml ethanol over night  
f) Centrifuge at maximum speed (benchtop centrifuge) remove ethanol and dry DNA 
for ∼20min at 65°C 
g) DNA is resuspended in 15-20µl ultrapure water for further use 
Elution buffer  NaCl  0.3mM 
   EDTA  3mM 
   Tris(pH 7.6) 30mM 
6.2.9 Preparation of CaCl2/RbCl2 competent cells  
1 ml overnight culture of the desired bacterial strain is taken for inoculation of 30ml LB. 
The culture is grown under constant stirring in a tempered water bath at +36°C to an 
OD600 of 0.5. Cells are collected by centrifugation (10 min at +4°C and 1700g) and kept ice 
cold for all further steps. The supernatant is decanted and the cells are resuspended in 20 
ml ice cold MOPS I solution and held on ice for 10 min. Centrifugation is repeated and 
cells are resuspended in 6 ml MOPS II solution and hold on ice for 30 min. After the final 
centrifugation cells are resuspended in 480 µl MOPS II and 180 µl 50% glycerol. 100 µl 
aliquots are stored at -80°C. 
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6.2.10 Transformation of CaCl2/RbCl2 competent cells 
Competent cells are thawed on ice (∼10 min). 2µl DNA is added to 100µl of competent 
cells and they are kept on ice for 30 min. Heat shock at +42°C for 2min is performed 
(+36°C for transformation with plasmids carrying a temperature inducible promotor), 
followed by addition of 700 µl LB medium and shaking for 1 hour at +36°C. After that cells 
are stroke on agar plates, containing selective antibiotics. 
6.2.11 Electro competent cells 
1 ml overnight culture of the desired bacterial strain is taken for inoculation of 30ml LB. 
The culture is grown under constant stirring in a tempered water bath at +36°C to an 
OD600 of 0.5. Cells are kept on ice for 30min and then collected by centrifugation (10min 
at +4°C and 1700g). Cells are resuspended in 30 ml ice cold 10% glycerol and kept ice cold 
for all further steps. Centrifugation is repeated, cells are resuspended in 15 ml 10% 
glycerol. Centrifugation is repeated, cells are resuspended in 600µl 10% glycerol. After the 
final centrifugation for 5min cells are resuspended in 300 µl 10% glycerol. For 0.1/0.2 cm 
electroporation cuvettes 50/100 µl aliquots are stored at -80°C, respectively. 
6.2.12 Transformation of electro competent cells 
Electroporation cuvettes and carriage are pre-cooled at -20°C. Electro competent cells are 
thawed on ice (∼10min). 2 µl DNA is added and the mix is transferred into electroporation 
cuvette. Pulse settings for E. coli in 0.1 cm cuvettes: 25 µF/1.8kV/200Ω (0.2cm cuvettes: 
25µF/2.5kV/200Ω) using the BioRad Gene Pulser II Electroporation System (BioRad, 
Munich, Germany). After the pulse is given cells are immediately mixed with 600 µl LB 
medium and kept shaking on +36°C for 1 hour. After that cells are stroke on agar plates 
containing selective antibiotics. 
6.3 Cultivation, growth and lysis in bacterial ghost production 
6.3.1 Cultivation medium for Escherichia coli  
E. coli are grown in LB medium which consists of 10g Peptone, 5g Yeast extract and 5g 
NaCl, adjusted to a pH of 7.4. For agar plates, 15 g/l agar is added to the media. All media 
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are autoclaved for 30 min at +121°C and 2bar. All chemicals were obtained from Carl 
Roth, Karlsruhe, Germany. 
6.3.2 Cultivation and storage of Escherichia coli  
E. coli are incubated in eprouvettes in 5ml LB at +36°C in a rotating incubator (Heraeus 
BK5060E, Frankfurt, Germany) over night. These precultures are further used for 
noseflask experiments or plasmid isolations. For long time storage glycerin stocks of the 
preculture are produced and stored at -80°C in 25% glycerol.. 
6.3.3 Growth, expression and lysis studies 
Clones are inoculated in 5ml LB medium each, supplemented with appropriate antibiotics 
and 2% glucose (when using IPTG inducible promotor). Eprouvettes are incubated in an 
incubation wheel at +36°C over night. 100ml noseflasks containing 30ml LB medium 
supplemented with antibiotics without glucose are prepared for inoculation with the 
overnight culture. At inoculation, the starting culture should reach an optical density 
(OD600) of roughly 0.10–0.15. Flasks are transferred to a 36°C water bath and stirred on a 
magnetic plate at 300 rpm. For induction of protein expression 2mM IPTG (60µl of 1M 
IPTG stock) is added when OD600 reaches 0.2–0.3. For LI cultures are transferred to a 
+42°C water bath when an OD600 0.4–0.5 is reached. For these studies throughout the 
whole experiment growth and protein expression of cultures is monitored.  
 by measuring the optical density at 600 nm (OD600) using Spectronic 20 Milton Roy 
Spectrophotometer (Milton Roy, Ivyland, USA) every 30 min, starting at time point 
of inoculation. OD values are illustrated as a graph in a logarithmic manner 
together with the cfu values in one diagram. 
 by determining the viable cell counts (colony forming units = cfu) 
The cfu are determined using a spiral plater (Don Whitley Scientific, Shipley, UK). 
Prior to plating bacterial samples are serially diluted in 0.85% NaCl (saline). 
Eprouvettes containing 9 ml saline are used for 1:10 dilutions (10
1
): 9ml saline + 
1ml culture. Eprouvettes containing 9.9 ml saline are used for 1:100 dilutions 
(10
2
): 9.9 ml saline + 0.1ml culture 
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Dilutions according to the OD600 of growing and lysing bacterial cultures are given as a 
reference in Tab 6-1: 
Growth  Lysis 
OD600 Dilution  OD600  Dilution 
0.05 – 0.5 10
4 
 1.5 – 1.0 
 
10
5 
0.5 – 1.0 10
5 
 1.0 – 0.5 
 
10
4 
   0.5 – 0.2 
 
10
3 
1.0 – 2.0 10
6 
 0.2 – 0.01 
 
10
2 
Tab 6-1 Dilutions for plating of bacterial cultures according to OD600 prior and after LI 
50 µl and 100 µl of the final dilution are plated in logarithmic manner on separate 
LB agar plates without any antibiotics. LB plates are incubated at +36°C over night. 
LB plates are counted using the ProtoCOL SR 92000 colony counter (Synoptics Ltd, 
Cambridge, UK). Cfu values are illustrated as a graph in a logarithmic manner 
together with the OD600 values in one diagram. 
Sample points for cfu analysis of growth and expression: 
o 0 min/ expression induction 
o 30 min 
o 60 min 
o 90 min 
o 120 min 
o 150 min 
o 180 min 
Sample points for cfu analysis of growth, expression and lysis: 
(time point of expression induction has to be evaluated) 
o -90 min 
o -60 min/ expression induction 
o -30 min 
o 0 min/lysis induction 
o 30 min 
o 60 min 
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o 90 min 
o 120 min 
 by light microscopy using Leitz DM-RB microscope (Wetzlar, Germany) 
Growth and lysis is observed by light microscopy. Growing and dividing cells are 
contrasted and are expected to become translucent after LI. 
Sample points for analysis of growth and expression: 
o 60 min 
o 120 min 
o 180 min 
Sample points for analysis of growth, expression and lysis: 
(time point of expression induction has to be evaluated, first microscopy sample is 
taken prior induction of expression) 
o -90 min/60 min/30 min 
o 0 min/lysis induction 
o 60 min 
o 120 min 
 By confirming the protein E and the recombinant protein expression by western 
blot analysis (6.2.5).  
1ml culture of each sample is spinned down and centrifuged in a bench top 
centrifuge at full speed for 3 min and the pellet is stored at -20°C for further 
analysis.  
Sample points for western blot analysis: 
(time point of expression induction has to be evaluated) 
o -90 min 
o -60 min 
o -30 min 
o 0 min/LI 
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o 30 min 
o 60 min 
o 90 min 
o 120 min 
6.3.4 Fermentation 
Fermentation is performed in a 30l stainless steel fermenter Techfors-S (Infors HT, 
Bottmingen, Switzerland) with a maximal working volume of 20l. Temperature is 
controlled by a Pt-100 temperature probe, acid and base pumps are used for pH-control 
and an InPro 6800 120mm Clarke electrode measures the oxygen level. Aeration is done 
with compressed air, the flow is controlled by a mass flow controller (Bronkhorst, Ruurlo, 
NL). The fermenter was rebuilt by changing the heating mechanism from hot water to 
steam, allowing a rapid temperature shift during the process. Steam is provided by a 
10kW steam generator (Infors-HT, Bottmingen, Switzerland), which allows in situ 
sterilization. A sterilizable sample port is located on the bottom of the vessel. The whole 
process is controlled using the software IRIS V.5.2 (Infors-HT, Bottmingen, Switzerland). 
Preparation  
Sterilization (+121°C, 2bar, 30 min) of the vessel containing 20l LB is done the day before 
fermentation. A sterile run over night ensures sterility of the unit. For preparation of the 
pre culture 4x500ml LB in 2 l Erlenmeyer flasks are autoclaved. At 5pm the day before 
fermentation appropriate antibiotics and glucose are added and the flasks are inoculated. 
Fermentation  
Prior to inoculation samples are taken before and after addition of antibiotics, and plated 
undiluted onto LB plates without antibiotics to determine the sterility of the medium. 
Fermenter is inoculated with preculture according to following equation: 
Volume of pre-culture (ml) necessary for inoculation = 
desired starting OD600 x Volume of medium in fermenter (ml) 
measured OD600 of the pre-culture 
Immediately after inoculation the first culture sample is taken. Sampling (∼40ml) 
continues every 30 min. Processing of the samples is done as described for OD600 
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measurements, cfu determination, western blot analysis and microscopy in 6.3.3. During 
fermentation process several parameters (temperature, oxygen flow, pO2, pH, stirring) 
are observed and controlled by the IRIS program. Temperature up shift is done manually. 
Killing 
Streptomycin and Tetracycline (200µg/ml and 20µg/ml end concentration, respectively) 
are added to the culture at the end of the lysis process and incubated for 1 hour. 
6.3.5 Harvesting and lyophilization  
Excerpted from BIRD-C SOP “Fermentation in Total” from 13.09.2005 
Sterile harvesting via separator 
− Enter the Param screen of fermenter and select Temp on  
− Set the Temp to e.g. 17°C 
− Switch OFF the Regulation for pH, antifoam and pO2 
− Make sure the tube for the culture supernatant (Klarphasenablauf) is fixed into a 
big bottle (big enough for 20l) that can be autoclaved afterwards 
− Plug in the heavy current 
− Switch on the separator (green switch I ) 
− Check the direction of rotation (red-white arrow) 
− Let the rotor warm-up 
− Make sure the movement of the oil is visible 
− Close valve 525, 527 and 029 
− Open valve 046 and 527 
− Set the stirring to 400 rpm and keep the flow still at the value of fermentation 
− Open the green rotary knob of the harvest outlet (turn to the left side) 
− Valve 029 (inlet controller) is closed and is opened slowly and carefully to a flow 
rate of ∼ 30-50l / hours 
− Valve 046 (responsible for the counter pressure against the inlet flow) is open and 
is closed slowly and carefully to reach a pressure of ∼ 1 bar 
Harvest the total fermenter 
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− The flow could be increased carefully to harvest the total fermenter (up to 10 or 
15l/min) 
− Close the green rotary knob of the harvest outlet (turn to the right side) 
− Bring the flow in the fermenter to 1 (devoid pressure in the fermenter) 
− Close valve, 029, 027, 046, 525 and 526 
− Fill 5 liters of autoclaved water into the fermenter 
− Open the green rotary knob of the harvest outlet (turn to the left side) again 
− Increase the flow again (up to 10 or 15 l / M) 
− Carefully open the valve 029 
− Let the water run through the separator 
− Close the green rotary knob of the harvest outlet (turn to the right side) again 
− Close the valve 029 completely 
− Switch off the separator and disconnect the power supply 
Washing of bacterial ghosts (BG) Ι 
− The BGs are collected into a sterile centrifuge tube. 
− The BG pellet is resuspended into sterile water and divided into 6 centrifuge flasks 
under the laminar 
Washing step:  
− The 6 flasks are filled up to ∼400ml 
− The centrifuge flasks are weighted in the laminar and brought to an identical 
weight 
− One centrifuge flask can be filled with 400ml 
− Using 6 centrifuge flasks ∼ 2400ml water will be used for washing at once 
− BGs are harvested by centrifugation in Hermle ZK 401 centrifuge at 8000rpm for 
15min and 4°C. 
− The supernatant is decanted carefully 
− Pellets can be stored now at 4°C for further washings on the next day 
Washing of bacterial ghosts (BG) ΙΙ 
Washing step:  
− The 6 flasks are filled with ∼100ml and the pellets are resuspended 
− properly 
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− The centrifuge flasks are weighted in the laminar and brought to an identical 
weight 
− One centrifuge flask can be filled with 400ml 
− Using 6 centrifuge flasks ∼ 2400ml water will be used for washing at once 
− BG are harvested by centrifugation in Hermle ZK 401 centrifuge at 8000rpm for 
15min and 4°C. 
− The supernatant is decanted carefully 
Washing step: 
− The 6 flasks are filled with ∼100ml and the pellets are resuspended properly 
− The centrifuge flasks are weighted in the laminar and brought to an identical 
weight 
− One centrifuge flask can be filled with 400ml 
− Using 6 centrifuge flasks ∼ 2400ml water will be used for washing at once 
− BGs are harvested by centrifugation in Hermle ZK 401 centrifuge at 8000rpm for 
15min and 4°C. 
− The supernatant is decanted carefully 
Washing step:  
− The 6 flasks are filled with ∼50l sterile water and the pellets are resuspended 
properly 
− The suspension of the 6 flasks are combined into one centrifuge flask 
− BGs are harvested by centrifugation in Hermle ZK 401 centrifuge at 8000rpm for 
15min and 4°C. 
− The supernatant is decanted carefully 
 
Lyophilization of the BGs 
− 11 lyophilization bottles are labeled and weighted on the analytical balance 
− Write down the weight of each bottle into the lab book 
− BG are resuspended in 200ml sterile distilled water 
− 10 lyophilization bottles are filled with 20ml of the BG suspension each (in total 
200ml) 
− The remaining BG suspension is transferred into bottle 11 for sterility testing 
− The tubes are stored at –80°C until lyophilization 
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6.3.6 Calculation of lysis efficiency and particles per mg 
Lysis Efficiency 
LE  = 1  	
	 . 100 
t0 ...time point of lysis induction 
t ...time point after lysis induction used for determination of LE; for this work t =120 min after 
induction 
Particles per mg 

 
 !"#!$%& () &*&+, !+-.$%&$/ 0,
12&*&+, 0#  
 
6.3.7 Sterility testing of the material 
∼10mg lyophilized material is resuspended into 5ml LB medium and used for: 
o “Koch’sches Plattengußverfahren”(1ml, 2ml)  
o plating on agar plates (100µl, 400µl) 
o liquid enrichment cultivation: 1ml inoculated into 5ml LB medium and 
incubated for 7 days at +28°C followed by plating of 100 and 400µl on agar 
plates 
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7. Appendix  
7.1 Symbols used in cloning strategies
Symbol 
 
 
Gene encoding the lacZ
 
 
Gene encoding the 
 
 
regulation of plasmid DNA replication by antisense RNA
  
 
 
 
intergenic region, origin of replication (+ 
 
 
 
meaning 
Gene encoding the lacZα protein  
α protein, coupled to an in vivo 
biotinylation sequence 
Ampicillin resistance cassette  
N-terminal part of the maltose binding 
protein 
repressor of lac operon 
origin of replication   
-) 
multiple cloning site 
Promotor of malE 
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7.2 Construction of pMal-467 
Sequence p467 was cloned in the MCS of the backbone vector pMal-p2x resulting in 
pMal-467: 
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7.3 Construction of pMal-467ivb 
Sequence p467 was cloned in the MCS of the backbone vector pMal-ivb resulting in pMal-
467ivb: 
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7.4 Construction of pMal-hm 
Sequence hm was cloned in the MCS of the backbone vector pMal-p2x resulting in pMal-
hm: 
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7.5 Construction of pMal-hmivb 
Sequence hm from 7.4 serves as template. Primer were designed to exclude the stop for 
cloning into pMal-ivb. PCR amplified hm sequence was cloned in the MCS of the backbone 
vector pMal-ivb resulting in pMal-hmivb: 
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